BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376:245-251. [PMID: 20609468 DOI: 10.1016/s0140-6736(10)60893-8] [Cited by in Crossref: 949] [Cited by in F6Publishing: 516] [Article Influence: 86.3] [Reference Citation Analysis]
Number Citing Articles
1 Li K, You J, Wu Q, Meng W, He Q, Yang B, Zhu C, Cao J. Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy. Acta Pharm Sin B 2021;11:2738-48. [PMID: 34589394 DOI: 10.1016/j.apsb.2021.01.002] [Reference Citation Analysis]
2 Dilley RL, Poh W, Gladstone DE, Herman JG, Showel MM, Karp JE, McDevitt MA, Pratz KW. Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro. Leuk Res 2014;38:411-7. [PMID: 24439051 DOI: 10.1016/j.leukres.2013.12.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
3 Kieffer Y, Bonneau C, Popova T, Rouzier R, Stern MH, Mechta-Grigoriou F. Clinical Interest of Combining Transcriptomic and Genomic Signatures in High-Grade Serous Ovarian Cancer. Front Genet 2020;11:219. [PMID: 32256521 DOI: 10.3389/fgene.2020.00219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Lin ZP, Ratner ES, Whicker ME, Lee Y, Sartorelli AC. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors. Mol Cancer Res 2014;12:381-93. [PMID: 24413181 DOI: 10.1158/1541-7786.MCR-13-0480] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
5 Reinbolt RE, Hays JL. The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies. Front Oncol 2013;3:237. [PMID: 24098868 DOI: 10.3389/fonc.2013.00237] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
6 Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, Yang C, Morizane R, Kochupurakkal BS, Do KT, Konstantinopoulos PA, Liu JF, Bonventre JV, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, D'Andrea AD. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov 2018;8:1404-21. [PMID: 30213835 DOI: 10.1158/2159-8290.CD-18-0474] [Cited by in Crossref: 124] [Cited by in F6Publishing: 81] [Article Influence: 41.3] [Reference Citation Analysis]
7 Gill SJ, Travers J, Pshenichnaya I, Kogera FA, Barthorpe S, Mironenko T, Richardson L, Benes CH, Stratton MR, McDermott U, Jackson SP, Garnett MJ. Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma. PLoS One 2015;10:e0140988. [PMID: 26505995 DOI: 10.1371/journal.pone.0140988] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 8.3] [Reference Citation Analysis]
8 Wiedemeyer WR, Beach JA, Karlan BY. Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System. Front Oncol 2014;4:34. [PMID: 24624361 DOI: 10.3389/fonc.2014.00034] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 6.0] [Reference Citation Analysis]
9 Peng G, Chun-Jen Lin C, Mo W, Dai H, Park YY, Kim SM, Peng Y, Mo Q, Siwko S, Hu R, Lee JS, Hennessy B, Hanash S, Mills GB, Lin SY. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun 2014;5:3361. [PMID: 24553445 DOI: 10.1038/ncomms4361] [Cited by in Crossref: 116] [Cited by in F6Publishing: 107] [Article Influence: 19.3] [Reference Citation Analysis]
10 Sun S, Osterman MD, Li M. Tissue specificity of DNA damage response and tumorigenesis. Cancer Biol Med 2019;16:396-414. [PMID: 31565474 DOI: 10.20892/j.issn.2095-3941.2019.0097] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
11 Krajewska M, Fehrmann RS, de Vries EG, van Vugt MA. Regulators of homologous recombination repair as novel targets for cancer treatment. Front Genet 2015;6:96. [PMID: 25852742 DOI: 10.3389/fgene.2015.00096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
12 Topatana W, Juengpanich S, Li S, Cao J, Hu J, Lee J, Suliyanto K, Ma D, Zhang B, Chen M, Cai X. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. J Hematol Oncol. 2020;13:118. [PMID: 32883316 DOI: 10.1186/s13045-020-00956-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
13 Liu Y, Meng J, Wang G. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. Drug Des Devel Ther 2018;12:3013-9. [PMID: 30271116 DOI: 10.2147/DDDT.S164553] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
14 Panou V, Røe OD. Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review. Int J Mol Sci 2020;21:E4327. [PMID: 32560575 DOI: 10.3390/ijms21124327] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
15 Hahnen E, Hauke J, Engel C, Neidhardt G, Rhiem K, Schmutzler RK. Germline Mutations in Triple-Negative Breast Cancer. Breast Care (Basel) 2017;12:15-9. [PMID: 28611536 DOI: 10.1159/000455999] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
16 Lokadasan R, James FV, Narayanan G, Prabhakaran PK. Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments. Ecancermedicalscience 2016;10:626. [PMID: 27110282 DOI: 10.3332/ecancer.2016.626] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
17 Tian S, Lou L, Tian M, Lu G, Tian J, Chen X. MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer. J Exp Clin Cancer Res 2020;39:143. [PMID: 32711558 DOI: 10.1186/s13046-020-01644-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Marmé F, Schneeweiss A. Targeted Therapies in Triple-Negative Breast Cancer. Breast Care (Basel) 2015;10:159-66. [PMID: 26557820 DOI: 10.1159/000433622] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
19 Scott CL, Becker MA, Haluska P, Samimi G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol. 2013;3:295. [PMID: 24363999 DOI: 10.3389/fonc.2013.00295] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 8.5] [Reference Citation Analysis]
20 Wilson AJ, Sarfo-Kantanka K, Barrack T, Steck A, Saskowski J, Crispens MA, Khabele D. Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib. Gynecol Oncol 2016;143:143-51. [PMID: 27444036 DOI: 10.1016/j.ygyno.2016.07.088] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
21 Topp MD, Hartley L, Cook M, Heong V, Boehm E, McShane L, Pyman J, McNally O, Ananda S, Harrell M, Etemadmoghadam D, Galletta L, Alsop K, Mitchell G, Fox SB, Kerr JB, Hutt KJ, Kaufmann SH, Australian Ovarian Cancer Study, Swisher EM, Bowtell DD, Wakefield MJ, Scott CL. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol 2014;8:656-68. [PMID: 24560445 DOI: 10.1016/j.molonc.2014.01.008] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 12.1] [Reference Citation Analysis]
22 Zhan T, Boutros M. Towards a compendium of essential genes - From model organisms to synthetic lethality in cancer cells. Crit Rev Biochem Mol Biol 2016;51:74-85. [PMID: 26627871 DOI: 10.3109/10409238.2015.1117053] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
23 Hong T, Lei G, Chen X, Li H, Zhang X, Wu N, Zhao Y, Zhang Y, Wang J. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. Redox Biol 2021;42:101928. [PMID: 33722571 DOI: 10.1016/j.redox.2021.101928] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
24 Fang B. Genetic interactions in translational research on cancer. World J Med Genet 2011; 1(1): 14-22 [DOI: 10.5496/wjmg.v1.i1.14] [Cited by in CrossRef: 3] [Article Influence: 0.3] [Reference Citation Analysis]
25 Liu L, Zhang Z, Zhang G, Wang T, Ma Y, Guo W. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with Olaparib. J Transl Med 2020;18:357. [PMID: 32951601 DOI: 10.1186/s12967-020-02528-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol. 2011;42:918-931. [PMID: 21683865 DOI: 10.1016/j.humpath.2011.03.003] [Cited by in Crossref: 681] [Cited by in F6Publishing: 604] [Article Influence: 68.1] [Reference Citation Analysis]
27 Cardoso FC, Goncalves S, Mele PG, Liria NC, Sganga L, Diaz Perez I, Podesta EJ, Solano AR. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population. Hum Genomics 2018;12:39. [PMID: 30103829 DOI: 10.1186/s40246-018-0171-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
28 Ratajska M, Koczkowska M, Żuk M, Gorczyński A, Kuźniacka A, Stukan M, Biernat W, Limon J, Wasąg B. Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer. Oncotarget 2017;8:101325-32. [PMID: 29254167 DOI: 10.18632/oncotarget.20722] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
29 Cashman R, Zilberberg A, Priel A, Philip H, Varvak A, Jacob A, Shoval I, Efroni S. A single nucleotide variant of human PARP1 determines response to PARP inhibitors. NPJ Precis Oncol 2020;4:10. [PMID: 32352035 DOI: 10.1038/s41698-020-0113-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Tommasi S, Pinto R, Danza K, Pilato B, Palumbo O, Micale L, De Summa S. miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype. Oncotarget 2016;7:80363-72. [PMID: 27385001 DOI: 10.18632/oncotarget.10345] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
31 Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, Chen Z, Kim S, Strychor S, Christner SM, Beumer J, Li C, Yue P, Chen A, Sica GL, Ramalingam SS, Kowalski J, Khuri FR, Sun SY. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med 2014;3:1579-94. [PMID: 25124282 DOI: 10.1002/cam4.317] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
32 Chavarri-Guerra Y, Slavin TP, Longoria-Lozano O, Weitzel JN. Genetic cancer predisposition syndromes among older adults. J Geriatr Oncol 2020;11:1054-60. [PMID: 31980412 DOI: 10.1016/j.jgo.2020.01.001] [Reference Citation Analysis]
33 Yonemori K, Tamura K, Kodaira M, Fujikawa K, Sagawa T, Esaki T, Shirakawa T, Hirai F, Yokoi Y, Kawata T, Hatano B, Takahashi Y. Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol 2016;78:525-31. [PMID: 27422301 DOI: 10.1007/s00280-016-3106-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
34 Kallarackal J, Burger F, Bianco S, Romualdi A, Schad M. A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer. PLoS One 2020;15:e0230313. [PMID: 32196521 DOI: 10.1371/journal.pone.0230313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK. Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol 2012;30:497-506. [PMID: 22231042 DOI: 10.1200/JCO.2011.38.6060] [Cited by in Crossref: 67] [Cited by in F6Publishing: 28] [Article Influence: 7.4] [Reference Citation Analysis]
36 Yun EJ, Lin CJ, Dang A, Hernandez E, Guo J, Chen WM, Allison J, Kim N, Kapur P, Brugarolas J, Wu K, He D, Lai CH, Lin H, Saha D, Baek ST, Chen BPC, Hsieh JT. Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation. Clin Cancer Res 2019;25:4542-51. [PMID: 31000589 DOI: 10.1158/1078-0432.CCR-18-3004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
37 Zhao L, Si CS, Yu Y, Lu JW, Zhuang Y. Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51. Cancer Sci 2019;110:3543-52. [PMID: 31541611 DOI: 10.1111/cas.14201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
38 Kedrin D, Gala MK. Genetics of the serrated pathway to colorectal cancer. Clin Transl Gastroenterol 2015;6:e84. [PMID: 25856207 DOI: 10.1038/ctg.2015.12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
39 Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 2013;3:68-81. [PMID: 23103855 DOI: 10.1158/2159-8290.cd-12-0049] [Cited by in Crossref: 295] [Cited by in F6Publishing: 190] [Article Influence: 32.8] [Reference Citation Analysis]
40 Wang Z, Gao J, Zhou J, Liu H, Xu C. Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer. J Gynecol Oncol 2019;30:e26. [PMID: 30740957 DOI: 10.3802/jgo.2019.30.e26] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
41 Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D, Olaussen KA, Brenner C, Soria JC, Castedo M, Kroemer G. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle 2013;12:877-83. [PMID: 23428903 DOI: 10.4161/cc.24034] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
42 Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Res 2015;17:33. [PMID: 25888415 DOI: 10.1186/s13058-015-0534-y] [Cited by in Crossref: 87] [Cited by in F6Publishing: 83] [Article Influence: 14.5] [Reference Citation Analysis]
43 Low SK, Zembutsu H, Nakamura Y. Breast cancer: The translation of big genomic data to cancer precision medicine. Cancer Sci 2018;109:497-506. [PMID: 29215763 DOI: 10.1111/cas.13463] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 13.3] [Reference Citation Analysis]
44 To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, Sporn MB, Liby KT. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res (Phila) 2014;7:698-707. [PMID: 24817481 DOI: 10.1158/1940-6207.CAPR-14-0047] [Cited by in Crossref: 46] [Cited by in F6Publishing: 25] [Article Influence: 6.6] [Reference Citation Analysis]
45 Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemother Pharmacol 2018;81:647-58. [PMID: 29464354 DOI: 10.1007/s00280-018-3532-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
46 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/so140-6736(10)62307-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Rescigno P, Cerillo I, Ruocco R, Condello C, De Placido S, Pensabene M. New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. Biomed Res Int 2013;2013:852839. [PMID: 24063014 DOI: 10.1155/2013/852839] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
48 Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2012;2:1048-63. [PMID: 22915751 DOI: 10.1158/2159-8290.CD-11-0336] [Cited by in Crossref: 280] [Cited by in F6Publishing: 163] [Article Influence: 31.1] [Reference Citation Analysis]
49 Lee SY, Oh SC. Ataxia telangiectasia mutated (ATM), could it be another useful biomarker for the successful treatment with the poly (ADP-ribose) polymerase inhibitor? Transl Gastroenterol Hepatol 2016;1:3. [PMID: 28138571 DOI: 10.21037/tgh.2016.03.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
50 Hall M, Rustin G. Recurrent ovarian cancer: when and how to treat. Curr Oncol Rep. 2011;13:459-471. [PMID: 22045509 DOI: 10.1007/s11912-011-0199-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
51 Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M, Zakynthinakis-Kyriakou N, Pavlidis N. PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca". Diagnostics (Basel) 2019;9:E55. [PMID: 31109041 DOI: 10.3390/diagnostics9020055] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 10.5] [Reference Citation Analysis]
52 Piao L, Kang D, Suzuki T, Masuda A, Dohmae N, Nakamura Y, Hamamoto R. The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells. Neoplasia 2014;16:257-64, 264.e2. [PMID: 24726141 DOI: 10.1016/j.neo.2014.03.002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 9.1] [Reference Citation Analysis]
53 Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol Oncol 2014;133:599-606. [PMID: 24631446 DOI: 10.1016/j.ygyno.2014.03.007] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 9.6] [Reference Citation Analysis]
54 Mantia-Smaldone GM, Edwards RP, Vlad AM. Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Manag Res 2011;3:25-38. [PMID: 21734812 DOI: 10.2147/CMR.S8759] [Cited by in Crossref: 5] [Cited by in F6Publishing: 31] [Article Influence: 0.5] [Reference Citation Analysis]
55 Feng FY, de Bono JS, Rubin MA, Knudsen KE. Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. Mol Cell 2015;58:925-34. [PMID: 26091341 DOI: 10.1016/j.molcel.2015.04.016] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 15.5] [Reference Citation Analysis]
56 Nero C, Vizzielli G, Lorusso D, Cesari E, Daniele G, Loverro M, Scambia G, Sette C. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine. J Exp Clin Cancer Res 2021;40:116. [PMID: 33789687 DOI: 10.1186/s13046-021-01917-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Symeonides S, Gourley C. Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge. Front Oncol 2015;5:229. [PMID: 26557500 DOI: 10.3389/fonc.2015.00229] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
58 Madariaga A, Bowering V, Ahrari S, Oza AM, Lheureux S. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer 2020;30:903-15. [PMID: 32276934 DOI: 10.1136/ijgc-2020-001288] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
59 Wang S, Wang H, Davis BC, Liang J, Cui R, Chen SJ, Xu ZX. PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1. Biochem Biophys Res Commun 2011;412:379-84. [PMID: 21821012 DOI: 10.1016/j.bbrc.2011.07.107] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
60 Wang J, Aroumougame A, Lobrich M, Li Y, Chen D, Chen J, Gong Z. PTIP associates with Artemis to dictate DNA repair pathway choice. Genes Dev 2014;28:2693-8. [PMID: 25512557 DOI: 10.1101/gad.252478.114] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 12.3] [Reference Citation Analysis]
61 Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res 2015;21:211-20. [PMID: 25348513 DOI: 10.1158/1078-0432.CCR-14-1816] [Cited by in Crossref: 92] [Cited by in F6Publishing: 57] [Article Influence: 13.1] [Reference Citation Analysis]
62 Fukui S, Nagasaka K, Miyagawa Y, Kikuchi-Koike R, Kawata Y, Kanda R, Ichinose T, Sugihara T, Hiraike H, Wada-Hiraike O, Sasajima Y, Ayabe T. The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-β/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget 2019;10:5932-48. [PMID: 31666925 DOI: 10.18632/oncotarget.27219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
63 Carruthers R, Chalmers AJ. The potential of PARP inhibitors in neuro-oncology. CNS Oncol 2012;1:85-97. [PMID: 25054302 DOI: 10.2217/cns.12.13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
64 Bundred N, Gardovskis J, Jaskiewicz J, Eglitis J, Paramonov V, McCormack P, Swaisland H, Cavallin M, Parry T, Carmichael J, Dixon JM. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest New Drugs 2013;31:949-58. [PMID: 23315029 DOI: 10.1007/s10637-012-9922-7] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
65 van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Invest New Drugs 2018;36:828-35. [PMID: 29313279 DOI: 10.1007/s10637-017-0551-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
66 Mieulet V, Garnier C, Kieffer Y, Guilbert T, Nemati F, Marangoni E, Renault G, Chamming's F, Vincent-Salomon A, Mechta-Grigoriou F. Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer. Sci Rep 2021;11:4219. [PMID: 33603134 DOI: 10.1038/s41598-021-83685-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
67 Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011;17:875-82. [PMID: 21706030 DOI: 10.1038/nm.2377] [Cited by in Crossref: 180] [Cited by in F6Publishing: 163] [Article Influence: 18.0] [Reference Citation Analysis]
68 Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EGE, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn SC. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011;22:1561-70. [PMID: 21135055 DOI: 10.1093/annonc/mdq624] [Cited by in Crossref: 124] [Cited by in F6Publishing: 107] [Article Influence: 11.3] [Reference Citation Analysis]
69 Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 2018;119:1075-85. [PMID: 30353045 DOI: 10.1038/s41416-018-0271-y] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 23.3] [Reference Citation Analysis]
70 Ganguly B, Dolfi SC, Rodriguez-Rodriguez L, Ganesan S, Hirshfield KM. Role of Biomarkers in the Development of PARP Inhibitors. Biomark Cancer 2016;8:15-25. [PMID: 26997874 DOI: 10.4137/BIC.S36679] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
71 Xu R, Huang Y, Mai J, Zhang G, Guo X, Xia X, Koay EJ, Qin G, Erm DR, Li Q, Liu X, Ferrari M, Shen H. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small 2013;9:1799-808. [PMID: 23293085 DOI: 10.1002/smll.201201510] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
72 Poveda A, Oaknin A, Romero I, Guerrero-Zotano A, Fariñas-Madrid L, Rodriguez-Freixinos V, Mallol P, Lopez-Reig R, Lopez-Guerrero JA. A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Sci Rep 2021;11:4433. [PMID: 33627685 DOI: 10.1038/s41598-021-82671-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Klattenhoff AW, Thakur M, Chu CS, Ray D, Habib SL, Kidane D. Loss of NEIL3 DNA glycosylase markedly increases replication associated double strand breaks and enhances sensitivity to ATR inhibitor in glioblastoma cells. Oncotarget 2017;8:112942-58. [PMID: 29348879 DOI: 10.18632/oncotarget.22896] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
74 Shao J, Yang J, Wang JN, Qiao L, Fan W, Gao QL, Feng YJ. Effect of BRCA2 mutation on familial breast cancer survival: A systematic review and meta-analysis. J Huazhong Univ Sci Technolog Med Sci 2015;35:629-34. [PMID: 26489613 DOI: 10.1007/s11596-015-1481-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
75 Lopez J, Banerjee S, Kaye SB. New developments in the treatment of ovarian cancer--future perspectives. Ann Oncol 2013;24 Suppl 10:x69-76. [PMID: 24265409 DOI: 10.1093/annonc/mdt475] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
76 Liu JF, Matulonis UA. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Curr Oncol Rep 2016;18:29. [PMID: 26984416 DOI: 10.1007/s11912-016-0515-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
77 Madariaga A, Lheureux S, Oza AM. Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers (Basel). 2019;11. [PMID: 30909618 DOI: 10.3390/cancers11030416] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
78 O'Sullivan Coyne G, Chen AP, Meehan R, Doroshow JH. PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. Drugs 2017;77:113-30. [PMID: 28078645 DOI: 10.1007/s40265-016-0688-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
79 Rigakos G, Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist 2012;17:956-62. [PMID: 22673632 DOI: 10.1634/theoncologist.2012-0028] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 7.3] [Reference Citation Analysis]
80 Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N, deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL; Australian Ovarian Cancer Study (AOCS). Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 2018;9:3970. [PMID: 30266954 DOI: 10.1038/s41467-018-05564-z] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 27.7] [Reference Citation Analysis]
81 Touboul C, Vidal F, Pasquier J, Lis R, Rafii A. Role of mesenchymal cells in the natural history of ovarian cancer: a review. J Transl Med 2014;12:271. [PMID: 25303976 DOI: 10.1186/s12967-014-0271-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
82 Deen SS, Riemer F, McLean MA, Gill AB, Kaggie JD, Grist JT, Crawford R, Latimer J, Baldwin P, Earl HM, Parkinson CA, Smith SA, Hodgkin C, Moore E, Jimenez-Linan M, Brodie CR, Addley HC, Freeman SJ, Moyle PL, Sala E, Graves MJ, Brenton JD, Gallagher FA. Sodium MRI with 3D-cones as a measure of tumour cellularity in high grade serous ovarian cancer. Eur J Radiol Open 2019;6:156-62. [PMID: 31032385 DOI: 10.1016/j.ejro.2019.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
83 Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, Raspagliesi F. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Drug Des Devel Ther 2018;12:1501-9. [PMID: 29881257 DOI: 10.2147/DDDT.S124447] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
84 Bell-McGuinn KM, Konner JA, Tew WP, Hensley ML, Iasonos A, Charpentier E, Mironov S, Sabbatini P, Aghajanian C. A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Int J Gynecol Cancer 2016;26:255-60. [PMID: 26745694 DOI: 10.1097/IGC.0000000000000591] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
85 Weil MK, Chen AP. PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer. 2011;35:7-50. [PMID: 21300207 DOI: 10.1016/j.currproblcancer.2010.12.002] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 7.9] [Reference Citation Analysis]
86 Chaudhary LN. Early stage triple negative breast cancer: Management and future directions. Semin Oncol 2020;47:201-8. [PMID: 32507668 DOI: 10.1053/j.seminoncol.2020.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
87 Helena JM, Joubert AM, Grobbelaar S, Nolte EM, Nel M, Pepper MS, Coetzee M, Mercier AE. Deoxyribonucleic Acid Damage and Repair: Capitalizing on Our Understanding of the Mechanisms of Maintaining Genomic Integrity for Therapeutic Purposes. Int J Mol Sci 2018;19:E1148. [PMID: 29641431 DOI: 10.3390/ijms19041148] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
88 Coward JI, Middleton K, Murphy F. New perspectives on targeted therapy in ovarian cancer. Int J Womens Health 2015;7:189-203. [PMID: 25678824 DOI: 10.2147/IJWH.S52379] [Cited by in Crossref: 66] [Cited by in F6Publishing: 48] [Article Influence: 11.0] [Reference Citation Analysis]
89 Lu Y, Liu Y, Pang Y, Pacak K, Yang C. Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy. Pharmacol Ther 2018;188:168-75. [PMID: 29621593 DOI: 10.1016/j.pharmthera.2018.03.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
90 Khabele D. The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer. Front Oncol 2014;4:111. [PMID: 24904826 DOI: 10.3389/fonc.2014.00111] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
91 Giornelli GH. Management of relapsed ovarian cancer: a review. Springerplus 2016;5:1197. [PMID: 27516935 DOI: 10.1186/s40064-016-2660-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
92 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0] [Cited by in Crossref: 1377] [Cited by in F6Publishing: 854] [Article Influence: 137.7] [Reference Citation Analysis]
93 Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biol Ther 2013;14:537-45. [PMID: 23760496 DOI: 10.4161/cbt.24349] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
94 Dick J, Aue V, Wesselmann S, Brédart A, Dolbeault S, Devilee P, Stoppa-Lyonnet D, Schmutzler RK, Rhiem K. Survey on Physicians' Knowledge and Training Needs in Genetic Counseling in Germany. Breast Care (Basel) 2021;16:389-95. [PMID: 34602945 DOI: 10.1159/000511136] [Reference Citation Analysis]
95 George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol 2017;14:284-96. [PMID: 27958297 DOI: 10.1038/nrclinonc.2016.191] [Cited by in Crossref: 90] [Cited by in F6Publishing: 87] [Article Influence: 18.0] [Reference Citation Analysis]
96 Guidugli L, Shimelis H, Masica DL, Pankratz VS, Lipton GB, Singh N, Hu C, Monteiro ANA, Lindor NM, Goldgar DE, Karchin R, Iversen ES, Couch FJ. Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. Am J Hum Genet 2018;102:233-48. [PMID: 29394989 DOI: 10.1016/j.ajhg.2017.12.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 11.0] [Reference Citation Analysis]
97 Baldwin P, Ohman AW, Tangutoori S, Dinulescu DM, Sridhar S. Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment. Int J Nanomedicine 2018;13:8063-74. [PMID: 30555227 DOI: 10.2147/IJN.S186881] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
98 Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013;19:1381-8. [PMID: 24202391 DOI: 10.1038/nm.3369] [Cited by in Crossref: 269] [Cited by in F6Publishing: 249] [Article Influence: 33.6] [Reference Citation Analysis]
99 Xu X, Wang Y, Guo W, Zhou Y, Lv C, Chen X, Liu K. The significance of the alteration of 8-OHdG in serous ovarian carcinoma. J Ovarian Res 2013;6:74. [PMID: 24165045 DOI: 10.1186/1757-2215-6-74] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
100 Chen A. PARP inhibitors: its role in treatment of cancer. Chin J Cancer. 2011;30:463-471. [PMID: 21718592 DOI: 10.5732/cjc.011.10111] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
101 Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013;15:R92. [PMID: 24286369 DOI: 10.1186/bcr3493] [Cited by in Crossref: 231] [Cited by in F6Publishing: 216] [Article Influence: 28.9] [Reference Citation Analysis]
102 Zhao Q, Yang J, Li L, Cao D, Yu M, Shen K; BGI Group. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. J Gynecol Oncol 2017;28:e39. [PMID: 28541631 DOI: 10.3802/jgo.2017.28.e39] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
103 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 674] [Article Influence: 80.0] [Reference Citation Analysis]
104 Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012;18:1655-1662. [PMID: 22291137 DOI: 10.1158/1078-0432.ccr-11-2890] [Cited by in Crossref: 159] [Cited by in F6Publishing: 76] [Article Influence: 17.7] [Reference Citation Analysis]
105 Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD. Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. Cancer Chemother Pharmacol 2017;80:165-75. [PMID: 28577239 DOI: 10.1007/s00280-017-3346-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
106 Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013;49:2972-2978. [PMID: 23810467 DOI: 10.1016/j.ejca.2013.05.020] [Cited by in Crossref: 116] [Cited by in F6Publishing: 101] [Article Influence: 14.5] [Reference Citation Analysis]
107 Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst. 2014;106:dju089. [PMID: 24842883 DOI: 10.1093/jnci/dju089] [Cited by in Crossref: 96] [Cited by in F6Publishing: 117] [Article Influence: 13.7] [Reference Citation Analysis]
108 Meyskens FL Jr, Gerner EW. Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach. Cancer Prev Res (Phila) 2011;4:628-32. [PMID: 21543341 DOI: 10.1158/1940-6207.CAPR-11-0162] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
109 Maugeri-Saccà M, Zeuner A, De Maria R. Therapeutic targeting of cancer stem cells. Front Oncol. 2011;1:10. [PMID: 22655230 DOI: 10.3389/fonc.2011.00010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
110 Horton JK, Stefanick DF, Prasad R, Gassman NR, Kedar PS, Wilson SH. Base excision repair defects invoke hypersensitivity to PARP inhibition. Mol Cancer Res 2014;12:1128-39. [PMID: 24770870 DOI: 10.1158/1541-7786.MCR-13-0502] [Cited by in Crossref: 52] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
111 Vescarelli E, Gerini G, Megiorni F, Anastasiadou E, Pontecorvi P, Solito L, De Vitis C, Camero S, Marchetti C, Mancini R, Benedetti Panici P, Dominici C, Romano F, Angeloni A, Marchese C, Ceccarelli S. MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1. J Exp Clin Cancer Res 2020;39:3. [PMID: 31898520 DOI: 10.1186/s13046-019-1490-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
112 Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, Matulonis U, Sand S, Tung N, Garber JE, Weitzel JN. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet 2012;205:34-41. [PMID: 22429596 DOI: 10.1016/j.cancergen.2012.01.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
113 Evans T, Matulonis U. PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol 2017;9:253-67. [PMID: 28491146 DOI: 10.1177/1758834016687254] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 13.8] [Reference Citation Analysis]
114 Song WH, Kim SH, Joung JY, Park WS, Seo HK, Chung J, Lee KH. Prostate Cancer in a Patient with a Family History of BRCA Mutation: a Case Report and Literature Review. J Korean Med Sci 2017;32:377-81. [PMID: 28049253 DOI: 10.3346/jkms.2017.32.2.377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
115 Hierro C, Azaro A, Argilés G, Elez E, Gómez P, Carles J, Rodon J. Unveiling changes in the landscape of patient populations in cancer early drug development. Oncotarget 2017;8:14158-72. [PMID: 27835915 DOI: 10.18632/oncotarget.13258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
116 Velagapudi UK, Langelier MF, Delgado-Martin C, Diolaiti ME, Bakker S, Ashworth A, Patel BA, Shao X, Pascal JM, Talele TT. Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity. J Med Chem 2019;62:5330-57. [PMID: 31042381 DOI: 10.1021/acs.jmedchem.8b01709] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
117 Jacob SL, Kiedrowski LA, Chae YK. The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy. Heliyon 2020;6:e03841. [PMID: 32420470 DOI: 10.1016/j.heliyon.2020.e03841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
118 Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM, McCue P, Gomella LG, Raj GV, Dicker AP, Brody JR, Pascal JM, Centenera MM, Butler LM, Tilley WD, Feng FY, Knudsen KE. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012;2:1134-49. [PMID: 22993403 DOI: 10.1158/2159-8290.CD-12-0120] [Cited by in Crossref: 204] [Cited by in F6Publishing: 145] [Article Influence: 22.7] [Reference Citation Analysis]
119 Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014;20:764-75. [PMID: 24240112 DOI: 10.1158/1078-0432.CCR-13-2287] [Cited by in Crossref: 499] [Cited by in F6Publishing: 267] [Article Influence: 62.4] [Reference Citation Analysis]
120 Adams DJ. The Valley of Death in anticancer drug development: a reassessment. Trends Pharmacol Sci 2012;33:173-80. [PMID: 22410081 DOI: 10.1016/j.tips.2012.02.001] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 5.2] [Reference Citation Analysis]
121 Lima ZS, Ghadamzadeh M, Arashloo FT, Amjad G, Ebadi MR, Younesi L. Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. J Hematol Oncol 2019;12:38. [PMID: 30975222 DOI: 10.1186/s13045-019-0725-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
122 Kaye SB. Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years. Ann Oncol 2016;27 Suppl 1:i1-3. [PMID: 27141062 DOI: 10.1093/annonc/mdw082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
123 Schiewer MJ, Mandigo AC, Gordon N, Huang F, Gaur S, de Leeuw R, Zhao SG, Evans J, Han S, Parsons T, Birbe R, McCue P, McNair C, Chand SN, Cendon-Florez Y, Gallagher P, McCann JJ, Poudel Neupane N, Shafi AA, Dylgjeri E, Brand LJ, Visakorpi T, Raj GV, Lallas CD, Trabulsi EJ, Gomella LG, Dicker AP, Kelly WK, Leiby BE, Knudsen B, Feng FY, Knudsen KE. PARP-1 regulates DNA repair factor availability. EMBO Mol Med 2018;10:e8816. [PMID: 30467127 DOI: 10.15252/emmm.201708816] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
124 Takaoka M, Miki Y. BRCA1 gene: function and deficiency. Int J Clin Oncol 2018;23:36-44. [PMID: 28884397 DOI: 10.1007/s10147-017-1182-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 10.5] [Reference Citation Analysis]
125 Vaidyanathan A, Sawers L, Gannon AL, Chakravarty P, Scott AL, Bray SE, Ferguson MJ, Smith G. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer 2016;115:431-41. [PMID: 27415012 DOI: 10.1038/bjc.2016.203] [Cited by in Crossref: 120] [Cited by in F6Publishing: 125] [Article Influence: 24.0] [Reference Citation Analysis]
126 Teyssonneau D, Margot H, Cabart M, Anonnay M, Sargos P, Vuong NS, Soubeyran I, Sevenet N, Roubaud G. Prostate cancer and PARP inhibitors: progress and challenges. J Hematol Oncol 2021;14:51. [PMID: 33781305 DOI: 10.1186/s13045-021-01061-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
127 Ledermann JA, El-Khouly F. PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions. Br J Cancer 2015;113 Suppl 1:S10-6. [PMID: 26669450 DOI: 10.1038/bjc.2015.395] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
128 AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecol Oncol 2016;143:379-88. [PMID: 27614696 DOI: 10.1016/j.ygyno.2016.08.328] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
129 Sand-Dejmek J, Adelmant G, Sobhian B, Calkins AS, Marto J, Iglehart DJ, Lazaro JB. Concordant and opposite roles of DNA-PK and the "facilitator of chromatin transcription" (FACT) in DNA repair, apoptosis and necrosis after cisplatin. Mol Cancer 2011;10:74. [PMID: 21679440 DOI: 10.1186/1476-4598-10-74] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
130 Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J. BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J Clin Invest 2016;126:2903-18. [PMID: 27454287 DOI: 10.1172/JCI70196] [Cited by in Crossref: 66] [Cited by in F6Publishing: 44] [Article Influence: 13.2] [Reference Citation Analysis]
131 Ying H, Lv J, Ying T, Jin S, Shao J, Wang L, Xu H, Yuan B, Yang Q. Gene-gene interaction network analysis of ovarian cancer using TCGA data. J Ovarian Res 2013;6:88. [PMID: 24314048 DOI: 10.1186/1757-2215-6-88] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
132 Fleury H, Carmona E, Morin VG, Meunier L, Masson JY, Tonin PN, Provencher D, Mes-Masson AM. Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines. Oncotarget 2017;8:40152-68. [PMID: 27374179 DOI: 10.18632/oncotarget.10308] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
133 Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25:32-40. [PMID: 24225019 DOI: 10.1093/annonc/mdt384] [Cited by in Crossref: 206] [Cited by in F6Publishing: 183] [Article Influence: 25.8] [Reference Citation Analysis]
134 Jerez Y, Márquez-Rodas I, Aparicio I, Alva M, Martín M, López-Tarruella S. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. Drugs 2020;80:131-46. [PMID: 31823331 DOI: 10.1007/s40265-019-01235-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
135 Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler RK. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol 2017;3:1378-85. [PMID: 28715532 DOI: 10.1001/jamaoncol.2017.1007] [Cited by in Crossref: 150] [Cited by in F6Publishing: 146] [Article Influence: 37.5] [Reference Citation Analysis]
136 van Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H, Vandertop PW, Würdinger T, Noske DP, Kaspers GJ, Cloos J. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2011;2:984-96. [PMID: 22184287 DOI: 10.18632/oncotarget.362] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 6.6] [Reference Citation Analysis]
137 Angeli D, Salvi S, Tedaldi G. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test? Int J Mol Sci 2020;21:E1128. [PMID: 32046255 DOI: 10.3390/ijms21031128] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
138 Hucl T, Gallmeier E. DNA repair: exploiting the Fanconi anemia pathway as a potential therapeutic target. Physiol Res 2011;60:453-65. [PMID: 21401292 DOI: 10.33549/physiolres.932115] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
139 Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecol Oncol 2016;142:548-56. [PMID: 27426307 DOI: 10.1016/j.ygyno.2016.07.092] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
140 Markman M. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer. Womens Health (Lond) 2018;14:1745505717750694. [PMID: 29313444 DOI: 10.1177/1745505717750694] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
141 Davar D, Beumer JH, Hamieh L, Tawbi H. Role of PARP inhibitors in cancer biology and therapy. Curr Med Chem 2012;19:3907-21. [PMID: 22788767 DOI: 10.2174/092986712802002464] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 8.7] [Reference Citation Analysis]
142 Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M. An update on PARP inhibitors--moving to the adjuvant setting. Nat Rev Clin Oncol 2015;12:27-41. [PMID: 25286972 DOI: 10.1038/nrclinonc.2014.163] [Cited by in Crossref: 234] [Cited by in F6Publishing: 215] [Article Influence: 33.4] [Reference Citation Analysis]
143 Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ. Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. Mol Cancer Ther 2017;16:2022-34. [PMID: 28619759 DOI: 10.1158/1535-7163.MCT-17-0098] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 9.8] [Reference Citation Analysis]
144 Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou VL, Murphy RF, Widemann BC, Figg WD, Kohn EC. Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. Clin Cancer Res 2017;23:1397-406. [PMID: 27663600 DOI: 10.1158/1078-0432.CCR-16-1546] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
145 Dale Rein I, Solberg Landsverk K, Micci F, Patzke S, Stokke T. Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation. Cell Cycle. 2015;14:3248-3260. [PMID: 26312527 DOI: 10.1080/15384101.2015.1085137] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
146 Al-Mugotir M, Lovelace JJ, George J, Bessho M, Pal D, Struble L, Kolar C, Rana S, Natarajan A, Bessho T, Borgstahl GEO. Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interaction. PLoS One 2021;16:e0248941. [PMID: 33784323 DOI: 10.1371/journal.pone.0248941] [Reference Citation Analysis]
147 Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis PA, Boyle F, Friedlander M. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. Br J Cancer 2019;120:279-85. [PMID: 30655615 DOI: 10.1038/s41416-018-0349-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
148 Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science 2017;355:1152-8. [PMID: 28302823 DOI: 10.1126/science.aam7344] [Cited by in Crossref: 882] [Cited by in F6Publishing: 817] [Article Influence: 220.5] [Reference Citation Analysis]
149 Ma J, Deng H, Li J, Hu S, Yang Y, Liu S, Han X. Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials. Cancer Manag Res 2019;11:3061-78. [PMID: 31114351 DOI: 10.2147/CMAR.S191107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
150 Lin ZP, Al Zouabi NN, Xu ML, Bowen NE, Wu TL, Lavi ES, Huang PH, Zhu YL, Kim B, Ratner ES. In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer. Sci Rep 2021;11:8042. [PMID: 33850183 DOI: 10.1038/s41598-021-87325-5] [Reference Citation Analysis]
151 Senhaji Mouhri Z, Goodfellow E, Jean-Claude B. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells. BMC Cancer 2017;17:540. [PMID: 28800752 DOI: 10.1186/s12885-017-3504-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
152 Zhu Y, Liu J, Park J, Rai P, Zhai RG. Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies. Pharmacol Ther 2019;200:27-41. [PMID: 30974124 DOI: 10.1016/j.pharmthera.2019.04.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
153 Wason JM, Mander AP. The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected. Stat Methods Med Res 2015;24:909-19. [PMID: 22179821 DOI: 10.1177/0962280211432192] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
154 Min BJ, Lee WS, Seo ME, Lee KH, Jeong SY, Ku JL, Kim YH, Shin SW, Kim JH. Development and Validation of Targeted Gene Sequencing Panel Based Companion Diagnostic for Korean Patients with Solid Tumors. Cancers (Basel) 2021;13:5112. [PMID: 34680263 DOI: 10.3390/cancers13205112] [Reference Citation Analysis]
155 Givel AM, Kieffer Y, Scholer-Dahirel A, Sirven P, Cardon M, Pelon F, Magagna I, Gentric G, Costa A, Bonneau C, Mieulet V, Vincent-Salomon A, Mechta-Grigoriou F. miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat Commun 2018;9:1056. [PMID: 29535360 DOI: 10.1038/s41467-018-03348-z] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 28.7] [Reference Citation Analysis]
156 Sharma P. Biology and Management of Patients With Triple-Negative Breast Cancer. Oncologist 2016;21:1050-62. [PMID: 27401886 DOI: 10.1634/theoncologist.2016-0067] [Cited by in Crossref: 87] [Cited by in F6Publishing: 88] [Article Influence: 17.4] [Reference Citation Analysis]
157 Oser MG, Fonseca R, Chakraborty AA, Brough R, Spektor A, Jennings RB, Flaifel A, Novak JS, Gulati A, Buss E, Younger ST, McBrayer SK, Cowley GS, Bonal DM, Nguyen QD, Brulle-Soumare L, Taylor P, Cairo S, Ryan CJ, Pease EJ, Maratea K, Travers J, Root DE, Signoretti S, Pellman D, Ashton S, Lord CJ, Barry ST, Kaelin WG Jr. Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov 2019;9:230-47. [PMID: 30373918 DOI: 10.1158/2159-8290.CD-18-0389] [Cited by in Crossref: 52] [Cited by in F6Publishing: 36] [Article Influence: 17.3] [Reference Citation Analysis]
158 Higgins MJ, Baselga J. Breast cancer in 2010: Novel targets and therapies for a personalized approach. Nat Rev Clin Oncol. 2011;8:65-66. [PMID: 21278769 DOI: 10.1038/nrclinonc.2010.217] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
159 Cunnea P, Fotopoulou C, Ploski J, Trillsch F, Mahner S, Kessler M. Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies. Cancers (Basel) 2021;13:3349. [PMID: 34283069 DOI: 10.3390/cancers13133349] [Reference Citation Analysis]
160 Slavin TP, Weitzel JN, Neuhausen SL, Schrader KA, Oliveira C, Karam R. Genetics of gastric cancer: what do we know about the genetic risks? Transl Gastroenterol Hepatol 2019;4:55. [PMID: 31463414 DOI: 10.21037/tgh.2019.07.02] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
161 Terlikowska KM, Witkowska AM, Zujko ME, Dobrzycka B, Terlikowski SJ. Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer. Int J Mol Sci 2014;15:21703-22. [PMID: 25429431 DOI: 10.3390/ijms151221703] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
162 Liu G, Yang D, Rupaimoole R, Pecot CV, Sun Y, Mangala LS, Li X, Ji P, Cogdell D, Hu L, Wang Y, Rodriguez-Aguayo C, Lopez-Berestein G, Shmulevich I, De Cecco L, Chen K, Mezzanzanica D, Xue F, Sood AK, Zhang W. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst 2015;107:djv108. [PMID: 25995442 DOI: 10.1093/jnci/djv108] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 10.7] [Reference Citation Analysis]
163 Aly A, Ganesan S. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol 2011;3:66-74. [PMID: 21278454 DOI: 10.1093/jmcb/mjq055] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 7.4] [Reference Citation Analysis]
164 Mariappan L, Jiang XY, Jackson J, Drew Y. Emerging treatment options for ovarian cancer: focus on rucaparib. Int J Womens Health 2017;9:913-24. [PMID: 29290694 DOI: 10.2147/IJWH.S151194] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
165 Nguyen L, W M Martens J, Van Hoeck A, Cuppen E. Pan-cancer landscape of homologous recombination deficiency. Nat Commun 2020;11:5584. [PMID: 33149131 DOI: 10.1038/s41467-020-19406-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 39.0] [Reference Citation Analysis]
166 Basu B, Sandhu SK, de Bono JS. PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. Drugs 2012;72:1579-90. [PMID: 22834679 DOI: 10.2165/11635510-000000000-00000] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
167 Meindl A, Ditsch N, Kast K, Rhiem K, Schmutzler RK. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int. 2011;108:323-330. [PMID: 21637635 DOI: 10.3238/arztebl.2011.0323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 44] [Article Influence: 0.9] [Reference Citation Analysis]
168 Sun C, Li N, Ding D, Weng D, Meng L, Chen G, Ma D. The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis. PLoS One. 2014;9:e95285. [PMID: 24788697 DOI: 10.1371/journal.pone.0095285] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
169 McLellan JL, O'Neil NJ, Barrett I, Ferree E, van Pel DM, Ushey K, Sipahimalani P, Bryan J, Rose AM, Hieter P. Synthetic lethality of cohesins with PARPs and replication fork mediators. PLoS Genet 2012;8:e1002574. [PMID: 22412391 DOI: 10.1371/journal.pgen.1002574] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
170 Day D, Siu LL. Approaches to modernize the combination drug development paradigm. Genome Med 2016;8:115. [PMID: 27793177 DOI: 10.1186/s13073-016-0369-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 7.6] [Reference Citation Analysis]
171 Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics. 2012;7:1225-1229. [PMID: 23069641 DOI: 10.4161/epi.22561] [Cited by in Crossref: 88] [Cited by in F6Publishing: 73] [Article Influence: 9.8] [Reference Citation Analysis]
172 Campelo RG, Massuti B, Mosquera J, Rosell R. 10(th) Congress on Lung Cancer-updates on clinical trials: goal. Transl Lung Cancer Res 2014;3:66-9. [PMID: 25806282 DOI: 10.3978/j.issn.2218-6751.2014.02.05] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
173 Murthy P, Muggia F. Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics. Ecancermedicalscience 2019;13:904. [PMID: 30915162 DOI: 10.3332/ecancer.2019.904] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
174 Mann M, Kumar S, Sharma A, Chauhan SS, Bhatla N, Kumar S, Bakhshi S, Gupta R, Kumar L. PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix. Oncotarget 2019;10:4262-75. [PMID: 31303961 DOI: 10.18632/oncotarget.27008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
175 Norris RE, Adamson PC, Nguyen VT, Fox E. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. Pediatr Blood Cancer 2014;61:145-50. [PMID: 24038812 DOI: 10.1002/pbc.24697] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
176 Guo T, Dong X, Xie S, Zhang L, Zeng P, Zhang L. Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer. Cancer Manag Res 2021;13:3081-100. [PMID: 33854378 DOI: 10.2147/CMAR.S292992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects. Cancer Manag Res. 2020;12:2731-2742. [PMID: 32368150 DOI: 10.2147/cmar.s211151] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
178 Gruosso T, Garnier C, Abelanet S, Kieffer Y, Lemesre V, Bellanger D, Bieche I, Marangoni E, Sastre-Garau X, Mieulet V, Mechta-Grigoriou F. MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas. Nat Commun 2015;6:8583. [PMID: 26456302 DOI: 10.1038/ncomms9583] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
179 Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ Jr, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM 3rd, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin Cancer Res 2015;21:1574-82. [PMID: 25589624 DOI: 10.1158/1078-0432.CCR-14-2565] [Cited by in Crossref: 80] [Cited by in F6Publishing: 45] [Article Influence: 13.3] [Reference Citation Analysis]
180 Holman LL, Lu KH. Genetic risk and gynecologic cancers. Hematol Oncol Clin North Am 2012;26:13-29. [PMID: 22244659 DOI: 10.1016/j.hoc.2011.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
181 Teo MY, O'Reilly EM. Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer? J Gastrointest Oncol 2016;7:738-49. [PMID: 27747088 DOI: 10.21037/jgo.2016.05.04] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
182 Hemming P, Kaur R, Meiser B, McKinley J, Young MA, James PA, Forrest LE. Oncologists' perspectives of telephone genetic counseling to facilitate germline BRCA1/2 testing for their patients with high-grade serous ovarian cancer. J Community Genet 2021;12:449-57. [PMID: 33956303 DOI: 10.1007/s12687-021-00530-7] [Reference Citation Analysis]
183 Macedo GS, Alemar B, Ashton-Prolla P. Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era. Genet Mol Biol 2019;42:215-31. [PMID: 31067289 DOI: 10.1590/1678-4685-GMB-2018-0104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
184 Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, Patel JD, Rose B, Zhang SR, Weatherly M, Nelakuditi V, Knight Johnson A, Helgeson M, Fischer D, Desai A, Sulai N, Ritterhouse L, Røe OD, Turaga KK, Huo D, Segal J, Kadri S, Li Z, Kindler HL, Churpek JE. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.J Clin Oncol. 2018;36:2863-2871. [PMID: 30113886 DOI: 10.1200/JCO.2018.78.5204] [Cited by in Crossref: 68] [Cited by in F6Publishing: 34] [Article Influence: 22.7] [Reference Citation Analysis]
185 Abu-Sanad A, Wang Y, Hasheminasab F, Panasci J, Noë A, Rosca L, Davidson D, Amrein L, Sharif-Askari B, Aloyz R, Panasci L. Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan. Front Pharmacol 2015;6:147. [PMID: 26257651 DOI: 10.3389/fphar.2015.00147] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
186 Li J, Bonkowski MS, Moniot S, Zhang D, Hubbard BP, Ling AJ, Rajman LA, Qin B, Lou Z, Gorbunova V, Aravind L, Steegborn C, Sinclair DA. A conserved NAD+ binding pocket that regulates protein-protein interactions during aging. Science 2017;355:1312-7. [PMID: 28336669 DOI: 10.1126/science.aad8242] [Cited by in Crossref: 91] [Cited by in F6Publishing: 83] [Article Influence: 22.8] [Reference Citation Analysis]
187 Solano AR, Liria NC, Jalil FS, Faggionato DM, Mele PG, Mampel A, Cardoso FC, Podesta EJ. BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina. Front Oncol 2018;8:323. [PMID: 30186769 DOI: 10.3389/fonc.2018.00323] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
188 Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer 2020;19:107. [PMID: 32563252 DOI: 10.1186/s12943-020-01227-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 30.0] [Reference Citation Analysis]
189 Schoonen PM, Kok YP, Wierenga E, Bakker B, Foijer F, Spierings DCJ, van Vugt MATM. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells. Mol Oncol 2019;13:2422-40. [PMID: 31529615 DOI: 10.1002/1878-0261.12573] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
190 Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082-1089. [PMID: 21233401 DOI: 10.1158/1078-0432.ccr-10-2560] [Cited by in Crossref: 345] [Cited by in F6Publishing: 204] [Article Influence: 34.5] [Reference Citation Analysis]
191 Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer 2017;3:31. [PMID: 28948212 DOI: 10.1038/s41523-017-0025-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 9.5] [Reference Citation Analysis]
192 Minchom A, Aversa C, Lopez J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther Adv Med Oncol 2018;10:1758835918786658. [PMID: 30023007 DOI: 10.1177/1758835918786658] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 21.7] [Reference Citation Analysis]
193 Sama AR, Schilder RJ. Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management. Int J Womens Health 2014;6:149-57. [PMID: 24511245 DOI: 10.2147/IJWH.S40889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
194 Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget 2017;8:44073-81. [PMID: 28454122 DOI: 10.18632/oncotarget.17237] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
195 Buchtel KM, Vogel Postula KJ, Weiss S, Williams C, Pineda M, Weissman SM. FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices. J Genet Couns 2018;27:131-9. [PMID: 28780754 DOI: 10.1007/s10897-017-0130-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
196 Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013;19:5003-5015. [PMID: 23881923 DOI: 10.1158/1078-0432.ccr-13-1391] [Cited by in Crossref: 281] [Cited by in F6Publishing: 164] [Article Influence: 35.1] [Reference Citation Analysis]
197 Mehibel M, Xu Y, Li CG, Moon EJ, Thakkar KN, Diep AN, Kim RK, Bloomstein JD, Xiao Y, Bacal J, Saldivar JC, Le QT, Cimprich KA, Rankin EB, Giaccia AJ. Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models. J Clin Invest 2021;131:146256. [PMID: 34060485 DOI: 10.1172/JCI146256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Yamamoto N, Nokihara H, Yamada Y, Goto Y, Tanioka M, Shibata T, Yamada K, Asahina H, Kawata T, Shi X, Tamura T. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci 2012;103:504-9. [PMID: 22145984 DOI: 10.1111/j.1349-7006.2011.02179.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
199 Vollebergh MA, Jonkers J, Linn SC. Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cell Mol Life Sci 2012;69:223-45. [PMID: 21922196 DOI: 10.1007/s00018-011-0809-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
200 Mateo J, Lord CJ, Serra V, Tutt A, Balmaña J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye SB, de Bono JS. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 2019;30:1437-47. [PMID: 31218365 DOI: 10.1093/annonc/mdz192] [Cited by in Crossref: 135] [Cited by in F6Publishing: 141] [Article Influence: 135.0] [Reference Citation Analysis]
201 Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, Todorova Kwan T, Morris R, Lauffer S, Nussenzweig A, Ramaswamy S, Benes CH, Haber DA, Maheswaran S, Birrer MJ, Zou L. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev 2017;31:318-32. [PMID: 28242626 DOI: 10.1101/gad.290957.116] [Cited by in Crossref: 167] [Cited by in F6Publishing: 153] [Article Influence: 41.8] [Reference Citation Analysis]
202 De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Front Oncol 2013;3:228. [PMID: 24062981 DOI: 10.3389/fonc.2013.00228] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 8.4] [Reference Citation Analysis]
203 Faraoni I, Graziani G. Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers (Basel) 2018;10:E487. [PMID: 30518089 DOI: 10.3390/cancers10120487] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 26.3] [Reference Citation Analysis]
204 Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 2011;108:3406-11. [PMID: 21300883 DOI: 10.1073/pnas.1013715108] [Cited by in Crossref: 333] [Cited by in F6Publishing: 294] [Article Influence: 33.3] [Reference Citation Analysis]
205 Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther 2013;12:1002-15. [PMID: 23729402 DOI: 10.1158/1535-7163.MCT-12-0813] [Cited by in Crossref: 68] [Cited by in F6Publishing: 41] [Article Influence: 8.5] [Reference Citation Analysis]
206 Leamon CP, Lovejoy CD, Nguyen B. Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer. Pharmgenomics Pers Med 2013;6:113-25. [PMID: 24109193 DOI: 10.2147/PGPM.S24943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
207 Wu X, Lippman SM. An intermittent approach for cancer chemoprevention. Nat Rev Cancer 2011;11:879-85. [PMID: 22071977 DOI: 10.1038/nrc3167] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
208 Lipkowitz S, Weissman AM. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer. 2011;11:629-643. [PMID: 21863050 DOI: 10.1038/nrc3120] [Cited by in Crossref: 242] [Cited by in F6Publishing: 234] [Article Influence: 24.2] [Reference Citation Analysis]
209 Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, Barrett A, Kraya AA, Anastopoulos IN, Yu S, Jiang Y, Chen H, Zhang NR, Hackman N, D'Andrea K, Daber R, Morrissette JJD, Mitra N, Feldman M, Domchek SM, Nathanson KL. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017;8:319. [PMID: 28831036 DOI: 10.1038/s41467-017-00388-9] [Cited by in Crossref: 116] [Cited by in F6Publishing: 101] [Article Influence: 29.0] [Reference Citation Analysis]
210 Hiss D. Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol 2012;2012:737981. [PMID: 22481932 DOI: 10.1155/2012/737981] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
211 Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 2012;11:201-14. [PMID: 22322254 DOI: 10.1038/nrd3651] [Cited by in Crossref: 186] [Cited by in F6Publishing: 152] [Article Influence: 20.7] [Reference Citation Analysis]
212 Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. Br J Cancer 2017;116:1021-6. [PMID: 28291774 DOI: 10.1038/bjc.2017.40] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
213 Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MA. Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. Transl Res 2013;161:156-64. [PMID: 23063585 DOI: 10.1016/j.trsl.2012.09.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
214 Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer 2016;16:110-20. [PMID: 26775620 DOI: 10.1038/nrc.2015.21] [Cited by in Crossref: 576] [Cited by in F6Publishing: 526] [Article Influence: 115.2] [Reference Citation Analysis]
215 Lok BH, Powell SN. Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement. Clin Cancer Res. 2012;18:6400-6406. [PMID: 23071261 DOI: 10.1158/1078-0432.CCR-11-3150] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 8.0] [Reference Citation Analysis]
216 Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, Gao H, Hao K, Willard MD, Xu J. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013;23:1422-1433. [PMID: 23788652 DOI: 10.1101/gr.154492.113] [Cited by in Crossref: 314] [Cited by in F6Publishing: 310] [Article Influence: 39.3] [Reference Citation Analysis]
217 Reiner T, Lacy J, Keliher EJ, Yang KS, Ullal A, Kohler RH, Vinegoni C, Weissleder R. Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents. Neoplasia 2012;14:169-77. [PMID: 22496617 DOI: 10.1593/neo.12414] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 8.2] [Reference Citation Analysis]
218 Sabatier R, Gonçalves A, Bertucci F, Capiello MA, Rousseau F, Lambaudie E, Chabannon C, Viens P, Extra JM. Are there candidates for high-dose chemotherapy in ovarian carcinoma? J Exp Clin Cancer Res 2012;31:87. [PMID: 23072336 DOI: 10.1186/1756-9966-31-87] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
219 Watkins JA, Irshad S, Grigoriadis A, Tutt AN. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res 2014;16:211. [PMID: 25093514 DOI: 10.1186/bcr3670] [Cited by in Crossref: 151] [Cited by in F6Publishing: 138] [Article Influence: 21.6] [Reference Citation Analysis]
220 Hutchinson L. Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2010;7:549. [PMID: 20922827 DOI: 10.1038/nrclinonc.2010.143] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
221 Stanley J, Klepczyk L, Keene K, Wei S, Li Y, Forero A, Grizzle W, Wielgos M, Brazelton J, LoBuglio AF, Yang ES. PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers. Breast Cancer Res Treat 2015;150:569-79. [PMID: 25833211 DOI: 10.1007/s10549-015-3359-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
222 Murata S, Zhang C, Finch N, Zhang K, Campo L, Breuer EK. Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine. Biomed Res Int 2016;2016:2346585. [PMID: 27642590 DOI: 10.1155/2016/2346585] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
223 Gadzicki D, Evans DG, Harris H, Julian-Reynier C, Nippert I, Schmidtke J, Tibben A, van Asperen CJ, Schlegelberger B. Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet 2011;2:53-69. [PMID: 22109790 DOI: 10.1007/s12687-011-0042-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 4.9] [Reference Citation Analysis]
224 Banerjee S, Gore M. Recent advances in systemic treatments for ovarian cancer. Cancer Imaging 2012;12:305-9. [PMID: 23022887 DOI: 10.1102/1470-7330.2012.9002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
225 de Groot JS, van Diest PJ, van Amersfoort M, Vlug EJ, Pan X, Ter Hoeve ND, Rosing H, Beijnen JH, Youssef SA, de Bruin A, Jonkers J, van der Wall E, Derksen PWB. Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice. Oncotarget 2017;8:60750-63. [PMID: 28977823 DOI: 10.18632/oncotarget.18490] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
226 Lenglet A, Liabeuf S, Bodeau S, Louvet L, Mary A, Boullier A, Lemaire-Hurtel AS, Jonet A, Sonnet P, Kamel S, Massy ZA. N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin. Toxins (Basel) 2016;8:E339. [PMID: 27854278 DOI: 10.3390/toxins8110339] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
227 Darici S, Alkhaldi H, Horne G, Jørgensen HG, Marmiroli S, Huang X. Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. J Clin Med 2020;9:E2934. [PMID: 32932888 DOI: 10.3390/jcm9092934] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
228 Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 2017;14:549-61. [PMID: 28534531 DOI: 10.1038/nrclinonc.2017.71] [Cited by in Crossref: 151] [Cited by in F6Publishing: 161] [Article Influence: 37.8] [Reference Citation Analysis]
229 Frederick BA, Gupta R, Atilano-Roque A, Su TT, Raben D. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models. Radiat Res 2020;194:519-31. [PMID: 32936912 DOI: 10.1667/RR15480.1] [Reference Citation Analysis]
230 Trenner A, Sartori AA. Harnessing DNA Double-Strand Break Repair for Cancer Treatment. Front Oncol 2019;9:1388. [PMID: 31921645 DOI: 10.3389/fonc.2019.01388] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 20.5] [Reference Citation Analysis]
231 Kast K, Rhiem K. Familial breast cancer - targeted therapy in secondary and tertiary prevention. Breast Care (Basel) 2015;10:27-31. [PMID: 25960722 DOI: 10.1159/000380756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
232 Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidziński M, Kim JW, Nam JH, Madry R, Hernández C, Mora PAR, Ryu SY, Milenkova T, Lowe ES, Barker L, Scambia G. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol 2020;38:1164-74. [PMID: 32073956 DOI: 10.1200/JCO.19.02745] [Cited by in Crossref: 51] [Cited by in F6Publishing: 17] [Article Influence: 51.0] [Reference Citation Analysis]
233 Norquist BM, Pennington KP, Agnew KJ, Harrell MI, Pennil CC, Lee MK, Casadei S, Thornton AM, Garcia RL, Walsh T, Swisher EM. Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing. Gynecol Oncol 2013;128:483-7. [PMID: 23262210 DOI: 10.1016/j.ygyno.2012.12.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
234 Castéra L, Krieger S, Rousselin A, Legros A, Baumann JJ, Bruet O, Brault B, Fouillet R, Goardon N, Letac O. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet. 2014;22:1305-1313. [PMID: 24549055 DOI: 10.1038/ejhg.2014.16] [Cited by in Crossref: 157] [Cited by in F6Publishing: 150] [Article Influence: 22.4] [Reference Citation Analysis]
235 Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70. [PMID: 23000897 DOI: 10.1038/nature11412] [Cited by in Crossref: 7046] [Cited by in F6Publishing: 6146] [Article Influence: 782.9] [Reference Citation Analysis]
236 Li S, Topatana W, Juengpanich S, Cao J, Hu J, Zhang B, Ma D, Cai X, Chen M. Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transduct Target Ther. 2020;5:241. [PMID: 33077733 DOI: 10.1038/s41392-020-00358-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
237 Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget 2017;8:47154-60. [PMID: 28454085 DOI: 10.18632/oncotarget.17005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
238 Koczkowska M, Zuk M, Gorczynski A, Ratajska M, Lewandowska M, Biernat W, Limon J, Wasag B. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases. Cancer Med 2016;5:1640-6. [PMID: 27167707 DOI: 10.1002/cam4.748] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
239 Chen Z, Yuan Y, Chen X, Chen J, Lin S, Li X, Du H. Systematic comparison of somatic variant calling performance among different sequencing depth and mutation frequency. Sci Rep 2020;10:3501. [PMID: 32103116 DOI: 10.1038/s41598-020-60559-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
240 Young A, Berry R, Holloway AF, Blackburn NB, Dickinson JL, Skala M, Phillips JL, Brettingham-Moore KH. RNA-seq profiling of a radiation resistant and radiation sensitive prostate cancer cell line highlights opposing regulation of DNA repair and targets for radiosensitization. BMC Cancer 2014;14:808. [PMID: 25369795 DOI: 10.1186/1471-2407-14-808] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
241 Li S, Zhang Y, Wang N, Guo R, Liu Q, Lv C, Wang J, Wang L, Yang QK. Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells. Cell Death Dis 2020;11:219. [PMID: 32249776 DOI: 10.1038/s41419-020-2408-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
242 Rhiem K, Schmutzler R. Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers. Breast Care (Basel) 2014;9:385-9. [PMID: 25759620 DOI: 10.1159/000369592] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
243 Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji J, Karnitz LM, Herman JG, Kinders RJ, Smith BD, Gore SD, Carraway HE, Showel MM, Gladstone DE, Levis MJ, Tsai HL, Rosner G, Chen A, Kaufmann SH, Karp JE. A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. Clin Cancer Res 2017;23:899-907. [PMID: 27551000 DOI: 10.1158/1078-0432.CCR-16-1274] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
244 Pop L, Suciu I, Ionescu O, Bacalbasa N, Ionescu P. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature. J Med Life 2021;14:17-20. [PMID: 33767780 DOI: 10.25122/jml-2020-0132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
245 Clark CC, Weitzel JN, O'Connor TR. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther 2012;11:1948-58. [PMID: 22778154 DOI: 10.1158/1535-7163.MCT-11-0597] [Cited by in Crossref: 53] [Cited by in F6Publishing: 22] [Article Influence: 5.9] [Reference Citation Analysis]
246 Na HY, Park JH, Shin SA, Lee S, Lee H, Chae H, Choung H, Kim N, Chung JH, Kim JE. Targeted Sequencing Revealed Distinct Mutational Profiles of Ocular and Extraocular Sebaceous Carcinomas. Cancers (Basel) 2021;13:4810. [PMID: 34638295 DOI: 10.3390/cancers13194810] [Reference Citation Analysis]
247 Weitzel JN, Blazer KR, MacDonald DJ, Culver JO, Offit K. Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin 2011;61:327-59. [PMID: 21858794 DOI: 10.3322/caac.20128] [Cited by in Crossref: 40] [Cited by in F6Publishing: 101] [Article Influence: 4.0] [Reference Citation Analysis]
248 Yang SH, Kuo TC, Wu H, Guo JC, Hsu C, Hsu CH, Tien YW, Yeh KH, Cheng AL, Kuo SH. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World J Gastroenterol 2016; 22(32): 7275-7288 [PMID: 27621574 DOI: 10.3748/wjg.v22.i32.7275] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
249 Bouberhan S, Philp L, Hill S, Al-Alem LF, Rueda B. Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. Cancers (Basel) 2020;12:E1206. [PMID: 32403357 DOI: 10.3390/cancers12051206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
250 Jiang Q, Greenberg RA. Deciphering the BRCA1 Tumor Suppressor Network. J Biol Chem 2015;290:17724-32. [PMID: 26048987 DOI: 10.1074/jbc.R115.667931] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
251 Guppy BJ, McManus KJ. Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition. Cell Oncol (Dordr) 2017;40:281-92. [PMID: 28462496 DOI: 10.1007/s13402-017-0323-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
252 Lodhia KA, Hadley AM, Haluska P, Scott CL. Prioritizing therapeutic targets using patient-derived xenograft models. Biochim Biophys Acta 2015;1855:223-34. [PMID: 25783201 DOI: 10.1016/j.bbcan.2015.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
253 Peralta S, Torraco A, Iommarini L, Diaz F. Mitochondrial Diseases Part III: Therapeutic interventions in mouse models of OXPHOS deficiencies. Mitochondrion 2015;23:71-80. [PMID: 25638392 DOI: 10.1016/j.mito.2015.01.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
254 Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med 2017;23:517-25. [PMID: 28288110 DOI: 10.1038/nm.4292] [Cited by in Crossref: 365] [Cited by in F6Publishing: 305] [Article Influence: 91.3] [Reference Citation Analysis]
255 Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O’Connor MJ, Wedge SR, Stratford IJ. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther. 2011;10:1949-1958. [PMID: 21825006 DOI: 10.1158/1535-7163.mct-11-0278] [Cited by in Crossref: 120] [Cited by in F6Publishing: 67] [Article Influence: 12.0] [Reference Citation Analysis]
256 Park SR, Chen A. Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment. Hematol Oncol Clin North Am 2012;26:649-70, ix. [PMID: 22520984 DOI: 10.1016/j.hoc.2012.02.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
257 Romeo M, Pardo JC, Martínez-Cardús A, Martínez-Balibrea E, Quiroga V, Martínez-Román S, Solé F, Margelí M, Mesía R. Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. Int J Mol Sci 2018;19:E3249. [PMID: 30347758 DOI: 10.3390/ijms19103249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
258 Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer 2016;115:1157-73. [PMID: 27736844 DOI: 10.1038/bjc.2016.311] [Cited by in Crossref: 113] [Cited by in F6Publishing: 101] [Article Influence: 22.6] [Reference Citation Analysis]
259 Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol 2019;20:570-80. [PMID: 30880072 DOI: 10.1016/S1470-2045(18)30905-7] [Cited by in Crossref: 73] [Cited by in F6Publishing: 40] [Article Influence: 36.5] [Reference Citation Analysis]
260 Jiang X, Li X, Li W, Bai H, Zhang Z. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J Cell Mol Med 2019;23:2303-13. [PMID: 30672100 DOI: 10.1111/jcmm.14133] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 20.0] [Reference Citation Analysis]
261 Weren RD, Mensenkamp AR, Simons M, Eijkelenboom A, Sie AS, Ouchene H, van Asseldonk M, Gomez-Garcia EB, Blok MJ, de Hullu JA, Nelen MR, Hoischen A, Bulten J, Tops BB, Hoogerbrugge N, Ligtenberg MJ. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas. Hum Mutat 2017;38:226-35. [PMID: 27767231 DOI: 10.1002/humu.23137] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
262 Lin D, Izadpanah R, Braun SE, Alt E. A novel model to characterize structure and function of BRCA1. Cell Biol Int 2018;42:34-44. [PMID: 28833843 DOI: 10.1002/cbin.10846] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
263 Wang Z, Sau S, Alsaab HO, Iyer AK. CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer. Nanomedicine 2018;14:1441-54. [PMID: 29678787 DOI: 10.1016/j.nano.2018.04.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
264 Purohit NK, Shah RG, Adant S, Hoepfner M, Shah GM, Beauregard JM. Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor. Oncotarget 2018;9:24693-706. [PMID: 29872498 DOI: 10.18632/oncotarget.25266] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
265 Smith SJ, Long A, Barrow JH, Macarthur DC, Coyle B, Grundy RG; Children's Cancer and Leukaemia Group Biological Studies Committee. Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target. Neuro Oncol 2011;13:1171-7. [PMID: 21849329 DOI: 10.1093/neuonc/nor115] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
266 Fojo T, Bates S. Mechanisms of resistance to PARP inhibitors--three and counting. Cancer Discov 2013;3:20-3. [PMID: 23319766 DOI: 10.1158/2159-8290.CD-12-0514] [Cited by in Crossref: 48] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
267 Prasad CB, Prasad SB, Yadav SS, Pandey LK, Singh S, Pradhan S, Narayan G. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci Rep 2017;7:12876. [PMID: 28993682 DOI: 10.1038/s41598-017-13232-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
268 Maxwell KN, Domchek SM. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 2012;9:520-8. [PMID: 22825375 DOI: 10.1038/nrclinonc.2012.123] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
269 McGonigle S, Chen Z, Wu J, Chang P, Kolber-Simonds D, Ackermann K, Twine NC, Shie JL, Miu JT, Huang KC, Moniz GA, Nomoto K. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling. Oncotarget 2015;6:41307-23. [PMID: 26513298 DOI: 10.18632/oncotarget.5846] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
270 Boysen G, Barbieri CE, Prandi D, Blattner M, Chae SS, Dahija A, Nataraj S, Huang D, Marotz C, Xu L, Huang J, Lecca P, Chhangawala S, Liu D, Zhou P, Sboner A, de Bono JS, Demichelis F, Houvras Y, Rubin MA. SPOP mutation leads to genomic instability in prostate cancer. Elife 2015;4:e09207. [PMID: 26374986 DOI: 10.7554/eLife.09207] [Cited by in Crossref: 83] [Cited by in F6Publishing: 66] [Article Influence: 13.8] [Reference Citation Analysis]
271 Klinakis A, Karagiannis D, Rampias T. Targeting DNA repair in cancer: current state and novel approaches. Cell Mol Life Sci 2020;77:677-703. [PMID: 31612241 DOI: 10.1007/s00018-019-03299-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
272 Park E. Data on cell cycle in breast cancer cell line, MDA-MB-231 with ferulic acid treatment. Data Brief 2016;7:107-10. [PMID: 26958638 DOI: 10.1016/j.dib.2016.02.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
273 Hedström E, Pederiva C, Farnebo J, Nodin B, Jirström K, Brennan DJ, Farnebo M. Downregulation of the cancer susceptibility protein WRAP53β in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcome. Cell Death Dis 2015;6:e1892. [PMID: 26426684 DOI: 10.1038/cddis.2015.250] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
274 Hyman DM, Spriggs DR. Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer. JAMA 2012;307:408-10. [PMID: 22274690 DOI: 10.1001/jama.2012.24] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
275 Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A, Poole CJ, Weigelt B, Kaye SB, Molife LR. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 2011;8:302-6. [PMID: 21468130 DOI: 10.1038/nrclinonc.2011.42] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 8.1] [Reference Citation Analysis]
276 Su JM, Thompson P, Adesina A, Li XN, Kilburn L, Onar-Thomas A, Kocak M, Chyla B, McKeegan E, Warren KE, Goldman S, Pollack IF, Fouladi M, Chen A, Giranda V, Boyett J, Kun L, Blaney SM. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report. Neuro Oncol 2014;16:1661-8. [PMID: 24908656 DOI: 10.1093/neuonc/nou103] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
277 Pan Y, Yang H, Claret FX. Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer. Cancer Biol Ther 2014;15:256-62. [PMID: 24495954 DOI: 10.4161/cbt.27823] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
278 Flaum N, Crosbie EJ, Edmondson RJ, Smith MJ, Evans DG. Epithelial ovarian cancer risk: A review of the current genetic landscape. Clin Genet 2020;97:54-63. [PMID: 31099061 DOI: 10.1111/cge.13566] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
279 Chase DM, Patel S, Shields K. Profile of olaparib in the treatment of advanced ovarian cancer. Int J Womens Health 2016;8:125-9. [PMID: 27186080 DOI: 10.2147/IJWH.S55906] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
280 Perez-Fidalgo JA, Iglesias M, Bohn U, Calvo E, Garcia Y, Guerra E, Manso L, Santaballa A, Gonzalez-Martin A. GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer. Future Sci OA 2019;5:FSO370. [PMID: 30820349 DOI: 10.4155/fsoa-2018-0107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
281 Gabbasov R, Benrubi ID, O'Brien SW, Krais JJ, Johnson N, Litwin S, Connolly DC. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. Cancer Biol Ther 2019;20:1035-45. [PMID: 30929564 DOI: 10.1080/15384047.2019.1595279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
282 Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol 2014;6:229-39. [PMID: 25342990 DOI: 10.1177/1758834014544121] [Cited by in Crossref: 120] [Cited by in F6Publishing: 118] [Article Influence: 17.1] [Reference Citation Analysis]
283 Moore KN, Monk BJ. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Oncologist 2016;21:954-63. [PMID: 27256873 DOI: 10.1634/theoncologist.2015-0268] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
284 Dean E, Middleton MR, Pwint T, Swaisland H, Carmichael J, Goodege-Kunwar P, Ranson M. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer. 2012;106:468-474. [PMID: 22223088 DOI: 10.1038/bjc.2011.555] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 10.2] [Reference Citation Analysis]
285 Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, Zhang W. Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics 2012;13:1523-35. [PMID: 23057551 DOI: 10.2217/pgs.12.137] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
286 Ito S, Murphy CG, Doubrovina E, Jasin M, Moynahan ME. PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells. PLoS One 2016;11:e0159341. [PMID: 27428646 DOI: 10.1371/journal.pone.0159341] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
287 Mansouri A, McGregor N, Dunn R, Dobbie S, Holmes J, Collins L, Nicum S. Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol. BMJ Open 2021;11:e041463. [PMID: 33452192 DOI: 10.1136/bmjopen-2020-041463] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Ip LR, Poulogiannis G, Viciano FC, Sasaki J, Kofuji S, Spanswick VJ, Hochhauser D, Hartley JA, Sasaki T, Gewinner CA. Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment. Oncotarget 2015;6:10548-62. [PMID: 25868852 DOI: 10.18632/oncotarget.3307] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
289 Myers SH, Ortega JA, Cavalli A. Synthetic Lethality through the Lens of Medicinal Chemistry. J Med Chem 2020;63:14151-83. [PMID: 33135887 DOI: 10.1021/acs.jmedchem.0c00766] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
290 Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016; 22(46): 10254-10259 [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
291 O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer 2018;124:1374-82. [PMID: 29338080 DOI: 10.1002/cncr.31218] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 17.7] [Reference Citation Analysis]
292 Mao Y, Huang X, Shuang Z, Lin G, Wang J, Duan F, Chen J, Li S. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation. Cancer Med 2018;7:1285-96. [PMID: 29479816 DOI: 10.1002/cam4.1318] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
293 Drew Y. The development of PARP inhibitors in ovarian cancer: from bench to bedside. Br J Cancer 2015;113 Suppl 1:S3-9. [PMID: 26669452 DOI: 10.1038/bjc.2015.394] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
294 Loizzi V, Ranieri G, Laforgia M, Gadaleta CD, Gargano G, Kardhashi A, De Liso M, Naglieri E, Del Vecchio V, Cicinelli E, Cormio G. PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective. Oncol Lett 2020;20:90. [PMID: 32831909 DOI: 10.3892/ol.2020.11951] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
295 Fang B, Mehran RJ, Heymach JV, Swisher SG. Predictive biomarkers in precision medicine and drug development against lung cancer. Chin J Cancer 2015;34:295-309. [PMID: 26134262 DOI: 10.1186/s40880-015-0028-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
296 McMullin RP, Wittner BS, Yang C, Denton-Schneider BR, Hicks D, Singavarapu R, Moulis S, Lee J, Akbari MR, Narod SA, Aldape KD, Steeg PS, Ramaswamy S, Sgroi DC. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Res 2014;16:R25. [PMID: 24625110 DOI: 10.1186/bcr3625] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
297 Lloyd RL, Wijnhoven PWG, Ramos-Montoya A, Wilson Z, Illuzzi G, Falenta K, Jones GN, James N, Chabbert CD, Stott J, Dean E, Lau A, Young LA. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene. 2020;39:4869-4883. [PMID: 32444694 DOI: 10.1038/s41388-020-1328-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 28.0] [Reference Citation Analysis]
298 Mukhopadhyay P, Horváth B, Kechrid M, Tanchian G, Rajesh M, Naura AS, Boulares AH, Pacher P. Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic Biol Med 2011;51:1774-88. [PMID: 21884784 DOI: 10.1016/j.freeradbiomed.2011.08.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 6.2] [Reference Citation Analysis]
299 Swindall AF, Stanley JA, Yang ES. PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis? Cancers (Basel) 2013;5:943-58. [PMID: 24202328 DOI: 10.3390/cancers5030943] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 7.9] [Reference Citation Analysis]
300 Aronson SJ, Rehm HL. Building the foundation for genomics in precision medicine. Nature 2015;526:336-42. [PMID: 26469044 DOI: 10.1038/nature15816] [Cited by in Crossref: 261] [Cited by in F6Publishing: 200] [Article Influence: 52.2] [Reference Citation Analysis]
301 Trinh XB, Tjalma WA, Dirix LY, Vermeulen PB, Peeters DJ, Bachvarov D, Plante M, Berns EM, Helleman J, Van Laere SJ, van Dam PA. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. PLoS One 2011;6:e22469. [PMID: 21799864 DOI: 10.1371/journal.pone.0022469] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
302 Itamochi H, Kigawa J. Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol 2012;17:430-40. [PMID: 22926640 DOI: 10.1007/s10147-012-0459-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
303 Dhillon KK, Swisher EM, Taniguchi T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci 2011;102:663-9. [PMID: 21205087 DOI: 10.1111/j.1349-7006.2010.01840.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 8.2] [Reference Citation Analysis]
304 Choi YE, Battelli C, Watson J, Liu J, Curtis J, Morse AN, Matulonis UA, Chowdhury D, Konstantinopoulos PA. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget 2014;5:2678-87. [PMID: 24798692 DOI: 10.18632/oncotarget.1929] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
305 Wang Y, Ung MH, Cantor S, Cheng C. Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer. Sci Rep 2017;7:15742. [PMID: 29146938 DOI: 10.1038/s41598-017-16138-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
306 Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011;10:351-64. [PMID: 21532565 DOI: 10.1038/nrd3374] [Cited by in Crossref: 194] [Cited by in F6Publishing: 173] [Article Influence: 19.4] [Reference Citation Analysis]
307 Zeng Y, Rucki AA, Che X, Zheng L. Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma. J Gastrointest Oncol 2017;8:441-8. [PMID: 28736631 DOI: 10.21037/jgo.2016.10.02] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
308 Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014;15:1207-14. [PMID: 25218906 DOI: 10.1016/S1470-2045(14)70391-2] [Cited by in Crossref: 362] [Cited by in F6Publishing: 176] [Article Influence: 51.7] [Reference Citation Analysis]
309 Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015;137:386-91. [PMID: 25818403 DOI: 10.1016/j.ygyno.2015.03.042] [Cited by in Crossref: 155] [Cited by in F6Publishing: 150] [Article Influence: 25.8] [Reference Citation Analysis]
310 Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dienstmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med 2018;10:e9172. [PMID: 30377213 DOI: 10.15252/emmm.201809172] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 32.0] [Reference Citation Analysis]
311 Lai E, Ziranu P, Spanu D, Dubois M, Pretta A, Tolu S, Camera S, Liscia N, Mariani S, Persano M, Migliari M, Donisi C, Demurtas L, Pusceddu V, Puzzoni M, Scartozzi M. BRCA-mutant pancreatic ductal adenocarcinoma. Br J Cancer 2021. [PMID: 34262146 DOI: 10.1038/s41416-021-01469-9] [Reference Citation Analysis]
312 Geenen JJJ, Linn SC, Beijnen JH, Schellens JHM. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. Clin Pharmacokinet 2018;57:427-37. [PMID: 29063517 DOI: 10.1007/s40262-017-0587-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 18.5] [Reference Citation Analysis]
313 Jiang M, Zhuang H, Xia R, Gan L, Wu Y, Ma J, Sun Y, Zhuang Z. KIF11 is required for proliferation and self-renewal of docetaxel resistant triple negative breast cancer cells. Oncotarget 2017;8:92106-18. [PMID: 29190901 DOI: 10.18632/oncotarget.20785] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
314 Nile DL, Rae C, Hyndman IJ, Gaze MN, Mairs RJ. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer 2016;16:621. [PMID: 27515310 DOI: 10.1186/s12885-016-2656-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
315 Audeh MW. Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition. Pharmgenomics Pers Med 2014;7:307-16. [PMID: 25342917 DOI: 10.2147/PGPM.S39765] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
316 Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.Br J Cancer. 2018;119:1401-1409. [PMID: 30353044 DOI: 10.1038/s41416-018-0274-8] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 22.3] [Reference Citation Analysis]
317 Ratner ES, Sartorelli AC, Lin ZP. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol 2012;24:564-71. [PMID: 22759740 DOI: 10.1097/CCO.0b013e3283564230] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
318 Brasseur K, Gévry N, Asselin E. Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget 2017;8:4008-42. [PMID: 28008141 DOI: 10.18632/oncotarget.14021] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 26.0] [Reference Citation Analysis]
319 Bahar E, Kim JY, Kim DC, Kim HS, Yoon H. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway. Int J Mol Sci 2021;22:3916. [PMID: 33920140 DOI: 10.3390/ijms22083916] [Reference Citation Analysis]
320 Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol 2014;7:70. [PMID: 25277503 DOI: 10.1186/s13045-014-0070-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 12.0] [Reference Citation Analysis]
321 Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R, Gianni L. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer 2014;111:651-9. [PMID: 25025963 DOI: 10.1038/bjc.2014.345] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 9.4] [Reference Citation Analysis]
322 Earp MA, Cunningham JM. DNA methylation changes in epithelial ovarian cancer histotypes. Genomics 2015;106:311-21. [PMID: 26363302 DOI: 10.1016/j.ygeno.2015.09.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
323 Mouchiroud L, Houtkooper RH, Auwerx J. NAD⁺ metabolism: a therapeutic target for age-related metabolic disease. Crit Rev Biochem Mol Biol 2013;48:397-408. [PMID: 23742622 DOI: 10.3109/10409238.2013.789479] [Cited by in Crossref: 125] [Cited by in F6Publishing: 123] [Article Influence: 15.6] [Reference Citation Analysis]
324 Warmoes M, Jaspers JE, Pham TV, Piersma SR, Oudgenoeg G, Massink MP, Waisfisz Q, Rottenberg S, Boven E, Jonkers J, Jimenez CR. Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer. Mol Cell Proteomics 2012;11:M111.013334. [PMID: 22366898 DOI: 10.1074/mcp.M111.013334] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
325 Kim H, George E, Ragland R, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown E, Simpkins F. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models. Clin Cancer Res 2017;23:3097-108. [PMID: 27993965 DOI: 10.1158/1078-0432.CCR-16-2273] [Cited by in Crossref: 118] [Cited by in F6Publishing: 80] [Article Influence: 23.6] [Reference Citation Analysis]
326 Wang J, Ding Q, Fujimori H, Motegi A, Miki Y, Masutani M. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors. Oncotarget 2016;7:7701-14. [PMID: 26713604 DOI: 10.18632/oncotarget.6715] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
327 Bonanno L, Favaretto A, Rugge M, Taron M, Rosell R. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs 2011;71:2231-46. [PMID: 22085382 DOI: 10.2165/11597700-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
328 Herold N, Wappenschmidt B, Markiefka B, Keupp K, Kröber S, Hahnen E, Schmutzler R, Rhiem K. Non-small cell neuroendocrine carcinoma of the ovary in a BRCA2-germline mutation carrier: A case report and brief review of the literature. Oncol Lett 2018;15:4093-6. [PMID: 29541174 DOI: 10.3892/ol.2018.7836] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
329 Cao X, Lu Y, Liu Y, Zhou Y, Song H, Zhang W, Davis D, Cui J, Hao S, Jung J, Wu Q, Park DM, Yang C. Combination of PARP inhibitor and temozolomide to suppress chordoma progression. J Mol Med (Berl) 2019;97:1183-93. [PMID: 31201471 DOI: 10.1007/s00109-019-01802-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
330 Pongor LS, Munkácsy G, Vereczkey I, Pete I, Győrffy B. Currently favored sampling practices for tumor sequencing can produce optimal results in the clinical setting. Sci Rep 2020;10:14403. [PMID: 32873813 DOI: 10.1038/s41598-020-71382-3] [Reference Citation Analysis]
331 Plummer R. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? Breast Cancer Res 2011;13:218. [PMID: 21884642 DOI: 10.1186/bcr2877] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
332 Girolimetti G, Perrone AM, Santini D, Barbieri E, Guerra F, Ferrari S, Zamagni C, De Iaco P, Gasparre G, Turchetti D. BRCA-associated ovarian cancer: from molecular genetics to risk management. Biomed Res Int 2014;2014:787143. [PMID: 25136623 DOI: 10.1155/2014/787143] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
333 Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. Onco Targets Ther 2017;10:5195-208. [PMID: 29138572 DOI: 10.2147/OTT.S139336] [Cited by in Crossref: 71] [Cited by in F6Publishing: 40] [Article Influence: 17.8] [Reference Citation Analysis]
334 Liu C, Gross N, Li Y, Li G, Wang Z, Zhong S, Li Y, Hu G. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells. J Cell Mol Med 2020;24:2444-50. [PMID: 31957270 DOI: 10.1111/jcmm.14929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
335 Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, Swenerton KD. Better therapeutic trials in ovarian cancer. J Natl Cancer Inst 2014;106:dju029. [PMID: 24627272 DOI: 10.1093/jnci/dju029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
336 Wibom C, Ghasimi S, Van Loo P, Brännström T, Trygg J, Lau C, Henriksson R, Bergenheim T, Andersson U, Rydén P, Melin B. EGFR gene variants are associated with specific somatic aberrations in glioma. PLoS One 2012;7:e47929. [PMID: 23236348 DOI: 10.1371/journal.pone.0047929] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
337 Rosenthal SH, Sun W, Zhang K, Liu Y, Nguyen Q, Gerasimova A, Nery C, Cheng L, Castonguay C, Hiller E, Li J, Elzinga C, Wolfson D, Smolgovsky A, Chen R, Buller-Burckle A, Catanese J, Grupe A, Lacbawan F, Owen R. Development and Validation of a 34-Gene Inherited Cancer Predisposition Panel Using Next-Generation Sequencing. Biomed Res Int 2020;2020:3289023. [PMID: 32090079 DOI: 10.1155/2020/3289023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
338 Arbini AA, Guerra F, Greco M, Marra E, Gandee L, Xiao G, Lotan Y, Gasparre G, Hsieh JT, Moro L. Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2. Oncogenesis 2013;2:e82. [PMID: 24336406 DOI: 10.1038/oncsis.2013.45] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
339 Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011;19:664-78. [PMID: 21575865 DOI: 10.1016/j.ccr.2011.04.010] [Cited by in Crossref: 297] [Cited by in F6Publishing: 281] [Article Influence: 29.7] [Reference Citation Analysis]
340 Burgess M, Puhalla S. BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different. Front Oncol 2014;4:19. [PMID: 24579064 DOI: 10.3389/fonc.2014.00019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
341 Veskimäe K, Staff S, Grönholm A, Pesu M, Laaksonen M, Nykter M, Isola J, Mäenpää J. Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry. Tumour Biol 2016;37:11991-9. [PMID: 27155850 DOI: 10.1007/s13277-016-5062-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
342 O'Neil NJ, van Pel DM, Hieter P. Synthetic lethality and cancer: cohesin and PARP at the replication fork. Trends Genet 2013;29:290-7. [PMID: 23333522 DOI: 10.1016/j.tig.2012.12.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
343 Zhang L, Zhang F, Zhang W, Chen L, Gao N, Men Y, Xu X, Jiang Y. Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells. Cancer Biol Ther 2015;16:1585-92. [PMID: 26382920 DOI: 10.1080/15384047.2015.1078021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
344 Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 2017;23:4066-76. [PMID: 28356425 DOI: 10.1158/1078-0432.CCR-16-2714] [Cited by in Crossref: 55] [Cited by in F6Publishing: 29] [Article Influence: 13.8] [Reference Citation Analysis]
345 Lim HJ, Ledger W. Targeted therapy in ovarian cancer. Womens Health (Lond) 2016;12:363-78. [PMID: 27215391 DOI: 10.2217/whe.16.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
346 Chen X, Peng F, Ji Y, Xiang H, Wang X, Liu T, Wang H, Han Y, Wang C, Zhang Y, Kong X, Lang JY. Brca2 deficiency drives gastrointestinal tumor formation and is selectively inhibited by mitomycin C. Cell Death Dis 2020;11:812. [PMID: 32980867 DOI: 10.1038/s41419-020-03013-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
347 Li M, Yu X. The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy. Oncogene 2015;34:3349-56. [PMID: 25220415 DOI: 10.1038/onc.2014.295] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 9.4] [Reference Citation Analysis]
348 Singh N, Pay SL, Bhandare SB, Arimpur U, Motea EA. Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. Cancers (Basel) 2020;12:E972. [PMID: 32295316 DOI: 10.3390/cancers12040972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
349 Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, García-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J, Reis-Filho JS, Greenberg RA, Robson ME, Turner NC. Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clin Cancer Res 2017;23:6708-20. [PMID: 28765325 DOI: 10.1158/1078-0432.CCR-17-0544] [Cited by in Crossref: 112] [Cited by in F6Publishing: 48] [Article Influence: 28.0] [Reference Citation Analysis]
350 Ratner ES, Zhu YL, Penketh PG, Berenblum J, Whicker ME, Huang PH, Lee Y, Ishiguro K, Zhu R, Sartorelli AC, Lin ZP. Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair. Br J Cancer 2016;114:777-86. [PMID: 26964031 DOI: 10.1038/bjc.2016.54] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
351 Kwon BS, Byun JM, Lee HJ, Jeong DH, Lee TH, Shin KH, Suh DS, Kim KH. Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review. Cancer Res Treat 2019;51:941-50. [PMID: 30309222 DOI: 10.4143/crt.2018.312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
352 Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL, Carmichael J. Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 2013;15:R88. [PMID: 24063698 DOI: 10.1186/bcr3484] [Cited by in Crossref: 123] [Cited by in F6Publishing: 117] [Article Influence: 17.6] [Reference Citation Analysis]
353 Wiggans AJ, Cass GK, Bryant A, Lawrie TA, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev 2015;:CD007929. [PMID: 25991068 DOI: 10.1002/14651858.CD007929.pub3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
354 Janzen DM, Paik DY, Rosales MA, Yep B, Cheng D, Witte ON, Kayadibi H, Ryan CM, Jung ME, Faull K, Memarzadeh S. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo. Mol Cancer Ther 2013;12:2917-28. [PMID: 24222661 DOI: 10.1158/1535-7163.MCT-13-0572] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
355 Joshi PM, Sutor SL, Huntoon CJ, Karnitz LM. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J Biol Chem 2014;289:9247-53. [PMID: 24554720 DOI: 10.1074/jbc.M114.551143] [Cited by in Crossref: 111] [Cited by in F6Publishing: 73] [Article Influence: 15.9] [Reference Citation Analysis]
356 Spratt DE, Zumsteg ZS, Feng FY, Tomlins SA. Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol 2016;13:597-610. [PMID: 27245282 DOI: 10.1038/nrclinonc.2016.76] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
357 Vazquez-Ortiz G, Chisholm C, Xu X, Lahusen TJ, Li C, Sakamuru S, Huang R, Thomas CJ, Xia M, Deng C. Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells. Breast Cancer Res. 2014;16:R67. [PMID: 24962108 DOI: 10.1186/bcr3682] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
358 Solimando DA Jr, Waddell JA. Nivolumab and Olaparib. Hosp Pharm 2015;50:356-66. [PMID: 26405320 DOI: 10.1310/hpj5005-356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
359 Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011;29:3008-15. [PMID: 21709188 DOI: 10.1200/JCO.2010.34.2980] [Cited by in Crossref: 365] [Cited by in F6Publishing: 213] [Article Influence: 36.5] [Reference Citation Analysis]
360 Liu FW, Tewari KS. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Curr Treat Options Oncol 2016;17:12. [PMID: 26931795 DOI: 10.1007/s11864-015-0378-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
361 Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 2017;9:eaal1645. [PMID: 28747513 DOI: 10.1126/scitranslmed.aal1645] [Cited by in Crossref: 96] [Cited by in F6Publishing: 89] [Article Influence: 32.0] [Reference Citation Analysis]
362 Lim JS, Collins D, Yap TA. Emerging strategies for the treatment of advanced small cell lung cancer. J Thorac Dis 2016;8:E1249-53. [PMID: 27867600 DOI: 10.21037/jtd.2016.10.46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
363 Zhang F, Lou L, Peng B, Song X, Reizes O, Almasan A, Gong Z. Nudix Hydrolase NUDT16 Regulates 53BP1 Protein by Reversing 53BP1 ADP-Ribosylation. Cancer Res 2020;80:999-1010. [PMID: 31911551 DOI: 10.1158/0008-5472.CAN-19-2205] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
364 Shin SH, Bode AM, Dong Z. Precision medicine: the foundation of future cancer therapeutics. NPJ Precis Oncol 2017;1:12. [PMID: 29872700 DOI: 10.1038/s41698-017-0016-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 11.3] [Reference Citation Analysis]
365 Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 2015;33:1397-406. [PMID: 25779564 DOI: 10.1200/JCO.2014.58.8848] [Cited by in Crossref: 223] [Cited by in F6Publishing: 132] [Article Influence: 37.2] [Reference Citation Analysis]
366 Plummer R, Stephens P, Aissat-Daudigny L, Cambois A, Moachon G, Brown PD, Campone M. Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer Chemother Pharmacol 2014;74:257-65. [PMID: 24880570 DOI: 10.1007/s00280-014-2486-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
367 Liu GY, Zhang W. Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status? Chin J Cancer 2012;31:1-4. [PMID: 22176776 DOI: 10.5732/cjc.011.10432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
368 Feng X, Koh DW. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells. Int J Oncol 2013;42:749-56. [PMID: 23254695 DOI: 10.3892/ijo.2012.1740] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
369 Boonen RACM, Vreeswijk MPG, van Attikum H. Functional Characterization of PALB2 Variants of Uncertain Significance: Toward Cancer Risk and Therapy Response Prediction. Front Mol Biosci 2020;7:169. [PMID: 33195396 DOI: 10.3389/fmolb.2020.00169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
370 Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, Halmos B. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis 2013;34:739-49. [PMID: 23275151 DOI: 10.1093/carcin/bgs393] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 6.7] [Reference Citation Analysis]
371 Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer 2012;12:587-98. [PMID: 22918414 DOI: 10.1038/nrc3342] [Cited by in Crossref: 352] [Cited by in F6Publishing: 337] [Article Influence: 39.1] [Reference Citation Analysis]
372 Ma W, Halweg CJ, Menendez D, Resnick MA. Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus. Proc Natl Acad Sci U S A 2012;109:6590-5. [PMID: 22493268 DOI: 10.1073/pnas.1118078109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
373 Łaniewski P, Ilhan ZE, Herbst-Kralovetz MM. The microbiome and gynaecological cancer development, prevention and therapy. Nat Rev Urol 2020;17:232-50. [PMID: 32071434 DOI: 10.1038/s41585-020-0286-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 41.0] [Reference Citation Analysis]
374 Shi C, Yang EJ, Tao S, Ren G, Mou PK, Shim JS. Natural products targeting cancer cell dependency. J Antibiot (Tokyo) 2021. [PMID: 34163025 DOI: 10.1038/s41429-021-00438-x] [Reference Citation Analysis]
375 Shuen AY, Foulkes WD. Inherited mutations in breast cancer genes--risk and response. J Mammary Gland Biol Neoplasia. 2011;16:3-15. [PMID: 21461995 DOI: 10.1007/s10911-011-9213-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
376 Tian S, Mi W, Zhang M, Xing L, Zhang C. Comprehensive analysis of mRNA-level and miRNA-level subpathway activities for identifying robust ovarian cancer prognostic signatures. J Cell Mol Med 2020;24:2582-92. [PMID: 31957240 DOI: 10.1111/jcmm.14968] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
377 Visconti R, Morra F, Guggino G, Celetti A. The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. Int J Mol Sci 2017;18:E1374. [PMID: 28653990 DOI: 10.3390/ijms18071374] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
378 Frey MK, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecol Oncol Res Pract 2017;4:4. [PMID: 28250960 DOI: 10.1186/s40661-017-0039-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
379 Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers 2016;2:16061. [PMID: 27558151 DOI: 10.1038/nrdp.2016.61] [Cited by in Crossref: 300] [Cited by in F6Publishing: 285] [Article Influence: 60.0] [Reference Citation Analysis]
380 Jiang X, Li W, Li X, Bai H, Zhang Z. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Manag Res 2019;11:4371-90. [PMID: 31191001 DOI: 10.2147/CMAR.S200524] [Cited by in Crossref: 47] [Cited by in F6Publishing: 24] [Article Influence: 23.5] [Reference Citation Analysis]
381 Shi Y, Zhou F, Jiang F, Lu H, Wang J, Cheng C. PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells. Chin J Cancer Res 2014;26:142-7. [PMID: 24826054 DOI: 10.3978/j.issn.1000-9604.2014.02.13] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
382 O'Sullivan CC, Moon DH, Kohn EC, Lee JM. Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. Front Oncol. 2014;4:42. [PMID: 24616882 DOI: 10.3389/fonc.2014.00042] [Cited by in Crossref: 35] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
383 Multani S, Saranath D. Genotypic distribution of single nucleotide polymorphisms in oral cancer: global scene. Tumour Biol 2016;37:14501-12. [PMID: 27651159 DOI: 10.1007/s13277-016-5322-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
384 King HO, Brend T, Payne HL, Wright A, Ward TA, Patel K, Egnuni T, Stead LF, Patel A, Wurdak H, Short SC. RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells. Stem Cell Reports 2017;8:125-39. [PMID: 28076755 DOI: 10.1016/j.stemcr.2016.12.005] [Cited by in F6Publishing: 53] [Reference Citation Analysis]
385 May T, Yang J, Shoni M, Liu S, He H, Gali R, Ng SK, Crum C, Berkowitz RS, Ng SW. BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2. Neoplasia 2013;15:600-8. [PMID: 23730208 DOI: 10.1593/neo.121674] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
386 Romero I, Bast RC. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012;153:1593-1602. [PMID: 22416079 DOI: 10.1210/en.2011-2123] [Cited by in Crossref: 183] [Cited by in F6Publishing: 172] [Article Influence: 20.3] [Reference Citation Analysis]
387 Westin SN, Herzog TJ, Coleman RL. Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs 2013;31:213-29. [PMID: 22661305 DOI: 10.1007/s10637-012-9837-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
388 Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol. 2011;4:16. [PMID: 21504625 DOI: 10.1186/1756-8722-4-16] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 8.7] [Reference Citation Analysis]
389 Sariyar M, Suhr S, Schlünder I. How Sensitive Is Genetic Data? Biopreserv Biobank 2017;15:494-501. [PMID: 28880588 DOI: 10.1089/bio.2017.0033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
390 Ratajska M, Krygier M, Stukan M, Kuźniacka A, Koczkowska M, Dudziak M, Śniadecki M, Dębniak J, Wydra D, Brozek I, Biernat W, Borg A, Limon J, Wasąg B. Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing. J Appl Genet 2015;56:193-8. [PMID: 25366421 DOI: 10.1007/s13353-014-0254-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
391 Suh DH, Kim JW, Kim K, Kim HJ, Lee KH. Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol 2013;24:66-82. [PMID: 23346316 DOI: 10.3802/jgo.2013.24.1.66] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
392 Wang Q, Peng H, Qi X, Wu M, Zhao X. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduct Target Ther 2020;5:137. [PMID: 32728057 DOI: 10.1038/s41392-020-0199-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
393 Zeng X, Jiang S, Ruan S, Guo Z, Guo J, Liu M, Ye C, Dong J. MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells. Mol Med Rep 2021;24:548. [PMID: 34080025 DOI: 10.3892/mmr.2021.12187] [Reference Citation Analysis]
394 Geng L, Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM. Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. PLoS One 2011;6:e28862. [PMID: 22194930 DOI: 10.1371/journal.pone.0028862] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
395 Gavande NS, VanderVere-Carozza PS, Hinshaw HD, Jalal SI, Sears CR, Pawelczak KS, Turchi JJ. DNA repair targeted therapy: The past or future of cancer treatment? Pharmacol Ther 2016;160:65-83. [PMID: 26896565 DOI: 10.1016/j.pharmthera.2016.02.003] [Cited by in Crossref: 195] [Cited by in F6Publishing: 175] [Article Influence: 39.0] [Reference Citation Analysis]
396 Vaclová T, Woods NT, Megías D, Gomez-Lopez S, Setién F, García Bueno JM, Macías JA, Barroso A, Urioste M, Esteller M, Monteiro ANA, Benítez J, Osorio A. Germline missense pathogenic variants in the BRCA1 BRCT domain, p.Gly1706Glu and p.Ala1708Glu, increase cellular sensitivity to PARP inhibitor olaparib by a dominant negative effect. Hum Mol Genet 2016;25:5287-99. [PMID: 27742776 DOI: 10.1093/hmg/ddw343] [Reference Citation Analysis]
397 Zhou D, Li J, Bui K, Learoyd M, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H. Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. Clin Pharmacokinet 2019;58:615-25. [PMID: 30357650 DOI: 10.1007/s40262-018-0714-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
398 Spoerri L, Gunasingh G, Haass NK. Fluorescence-Based Quantitative and Spatial Analysis of Tumour Spheroids: A Proposed Tool to Predict Patient-Specific Therapy Response. Front Digit Health 2021;3:668390. [PMID: 34713141 DOI: 10.3389/fdgth.2021.668390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
399 Goyal G, Fan T, Silberstein PT. Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target. Fam Cancer. 2016;15:359-366. [PMID: 26873719 DOI: 10.1007/s10689-016-9883-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
400 Liu Y, Lusk CM, Cho MH, Silverman EK, Qiao D, Zhang R, Scheurer ME, Kheradmand F, Wheeler DA, Tsavachidis S, Armstrong G, Zhu D, Wistuba II, Chow CB, Behrens C, Pikielny CW, Neslund-Dudas C, Pinney SM, Anderson M, Kupert E, Bailey-Wilson J, Gaba C, Mandal D, You M, de Andrade M, Yang P, Field JK, Liloglou T, Davies M, Lissowska J, Swiatkowska B, Zaridze D, Mukeriya A, Janout V, Holcatova I, Mates D, Milosavljevic S, Scelo G, Brennan P, McKay J, Liu G, Hung RJ, Christiani DC, Schwartz AG, Amos CI, Spitz MR. Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer. J Thorac Oncol 2018;13:1483-95. [PMID: 29981437 DOI: 10.1016/j.jtho.2018.06.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
401 Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui JL, Yuan C, Li T, Li W, Masuda A, Gu M, Bullock AJ, Chang DT, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar MD, Wollison BM, Khalaf N, Perez K, Syngal S, Aguirre AJ, Hahn WC, Meyerson ML, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Nowak JA, Wolpin BM. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med 2019;21:213-23. [PMID: 29961768 DOI: 10.1038/s41436-018-0009-5] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 21.7] [Reference Citation Analysis]
402 Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244-50. [PMID: 25366685 DOI: 10.1200/JCO.2014.56.2728] [Cited by in Crossref: 1000] [Cited by in F6Publishing: 536] [Article Influence: 142.9] [Reference Citation Analysis]
403 Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, Jayson G, Sludden J, Murray J, Jamieson D, Halford S, Acton G, Backholer Z, Mangano R, Boddy A, Curtin N, Plummer R. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer 2016;114:723-30. [PMID: 27002934 DOI: 10.1038/bjc.2016.41] [Cited by in Crossref: 91] [Cited by in F6Publishing: 72] [Article Influence: 18.2] [Reference Citation Analysis]
404 Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Bennett B, Parry D, Spencer S, Mann H, Matulonis U. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer 2016;115:1313-20. [PMID: 27824811 DOI: 10.1038/bjc.2016.348] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
405 Makohon-Moore A, Brosnan JA, Iacobuzio-Donahue CA. Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Med 2013;5:26. [PMID: 23673020 DOI: 10.1186/gm430] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
406 Moreno L, Linossi C, Esteban I, Gadea N, Carrasco E, Bonache S, Gutiérrez-Enríquez S, Cruz C, Díez O, Balmaña J. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics. Clin Transl Oncol 2016;18:981-7. [PMID: 26742938 DOI: 10.1007/s12094-015-1470-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
407 Pan MR, Hsieh HJ, Dai H, Hung WC, Li K, Peng G, Lin SY. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment. J Biol Chem 2012;287:6764-72. [PMID: 22219182 DOI: 10.1074/jbc.M111.287037] [Cited by in Crossref: 57] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
408 Thumser-Henner P, Nytko KJ, Rohrer Bley C. Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy. BMC Vet Res 2020;16:30. [PMID: 32005245 DOI: 10.1186/s12917-020-2247-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
409 Papa A, Caruso D, Strudel M, Tomao S, Tomao F. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. J Transl Med 2016;14:267. [PMID: 27634150 DOI: 10.1186/s12967-016-1027-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 9.6] [Reference Citation Analysis]
410 OʼSullivan Coyne G, Chen A, Kummar S. Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy. Curr Opin Oncol 2015;27:475-81. [PMID: 26447876 DOI: 10.1097/CCO.0000000000000238] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
411 Mukai T, Fujita S, Morita Y. Tankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2. Cells 2019;8:E195. [PMID: 30813388 DOI: 10.3390/cells8020195] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
412 Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, Syndikus I, Ralph C, Jain S, Varughese M, Parikh O, Crabb S, Robinson A, McLaren D, Birtle A, Tanguay J, Miranda S, Figueiredo I, Seed G, Bertan C, Flohr P, Ebbs B, Rescigno P, Fowler G, Ferreira A, Riisnaes R, Pereira R, Curcean A, Chandler R, Clarke M, Gurel B, Crespo M, Nava Rodrigues D, Sandhu S, Espinasse A, Chatfield P, Tunariu N, Yuan W, Hall E, Carreira S, de Bono JS. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020;21:162-74. [PMID: 31806540 DOI: 10.1016/S1470-2045(19)30684-9] [Cited by in Crossref: 178] [Cited by in F6Publishing: 91] [Article Influence: 89.0] [Reference Citation Analysis]
413 Stoppa-Lyonnet D. The biological effects and clinical implications of BRCA mutations: where do we go from here? Eur J Hum Genet 2016;24 Suppl 1:S3-9. [PMID: 27514841 DOI: 10.1038/ejhg.2016.93] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
414 Daniels MS, Burzawa JK, Brandt AC, Schmeler KM, Lu KH. A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges. Fam Cancer 2011;10:193-7. [PMID: 21246292 DOI: 10.1007/s10689-011-9418-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
415 Conrad LB, Lin KY, Nandu T, Gibson BA, Lea JS, Kraus WL. ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers. Mol Cancer Ther 2020;19:282-91. [PMID: 31594824 DOI: 10.1158/1535-7163.MCT-19-0569] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
416 Oei AL, van Leeuwen CM, Ahire VR, Rodermond HM, Ten Cate R, Westermann AM, Stalpers LJA, Crezee J, Kok HP, Krawczyk PM, Kanaar R, Franken NAP. Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia. Oncotarget 2017;8:28116-24. [PMID: 28427225 DOI: 10.18632/oncotarget.15922] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
417 Brandt S, Samartzis EP, Zimmermann AK, Fink D, Moch H, Noske A, Dedes KJ. Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer. BMC Cancer 2017;17:44. [PMID: 28073364 DOI: 10.1186/s12885-016-3026-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
418 Yip K, Alonzi R. Carbogen gas and radiotherapy outcomes in prostate cancer. Ther Adv Urol 2013;5:25-34. [PMID: 23372608 DOI: 10.1177/1756287212452195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
419 Chujan S, Suriyo T, Ungtrakul T, Pomyen Y, Satayavivad J. Potential candidate treatment agents for targeting of cholangiocarcinoma identified by gene expression profile analysis. Biomed Rep 2018;9:42-52. [PMID: 29930804 DOI: 10.3892/br.2018.1101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
420 Caffo O, Veccia A, Kinspergher S, Rizzo M, Maines F. Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice? Front Cell Dev Biol 2018;6:71. [PMID: 30234108 DOI: 10.3389/fcell.2018.00071] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
421 Sorensen G, Nagler EM, Hashimoto D, Dennerlein JT, Theron JV, Stoddard AM, Buxton O, Wallace LM, Kenwood C, Nelson CC, Tamers SL, Grant MP, Wagner G. Implementing an Integrated Health Protection/Health Promotion Intervention in the Hospital Setting: Lessons Learned From the Be Well, Work Well Study. J Occup Environ Med 2016;58:185-94. [PMID: 26849263 DOI: 10.1097/JOM.0000000000000592] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
422 Williamson CT, Kubota E, Hamill JD, Klimowicz A, Ye R, Muzik H, Dean M, Tu L, Gilley D, Magliocco AM, McKay BC, Bebb DG, Lees-Miller SP. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med 2012;4:515-27. [PMID: 22416035 DOI: 10.1002/emmm.201200229] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 10.1] [Reference Citation Analysis]
423 Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol 2013;7:567-79. [PMID: 23415752 DOI: 10.1016/j.molonc.2012.12.007] [Cited by in Crossref: 84] [Cited by in F6Publishing: 85] [Article Influence: 10.5] [Reference Citation Analysis]
424 Orth M, Lauber K, Niyazi M, Friedl AA, Li M, Maihöfer C, Schüttrumpf L, Ernst A, Niemöller OM, Belka C. Current concepts in clinical radiation oncology. Radiat Environ Biophys 2014;53:1-29. [PMID: 24141602 DOI: 10.1007/s00411-013-0497-2] [Cited by in Crossref: 92] [Cited by in F6Publishing: 86] [Article Influence: 11.5] [Reference Citation Analysis]
425 Sharma P. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. Curr Treat Options Oncol 2018;19:22. [PMID: 29656345 DOI: 10.1007/s11864-018-0539-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 10.7] [Reference Citation Analysis]
426 Sorensen G, Peters S, Nielsen K, Nagler E, Karapanos M, Wallace L, Burke L, Dennerlein JT, Wagner GR. Improving Working Conditions to Promote Worker Safety, Health, and Wellbeing for Low-Wage Workers: The Workplace Organizational Health Study. Int J Environ Res Public Health 2019;16:E1449. [PMID: 31022886 DOI: 10.3390/ijerph16081449] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
427 Schaue D, Mcbride WH. Opportunities and challenges of radiotherapy for treating cancer. Nat Rev Clin Oncol 2015;12:527-40. [DOI: 10.1038/nrclinonc.2015.120] [Cited by in Crossref: 174] [Cited by in F6Publishing: 175] [Article Influence: 29.0] [Reference Citation Analysis]
428 Patel L, Parker B, Yang D, Zhang W. Translational genomics in cancer research: converting profiles into personalized cancer medicine. Cancer Biol Med 2013;10:214-20. [PMID: 24349831 DOI: 10.7497/j.issn.2095-3941.2013.04.005] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
429 van der Wijst MG, Huisman C, Mposhi A, Roelfes G, Rots MG. Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion. Mol Oncol 2015;9:1259-73. [PMID: 25841766 DOI: 10.1016/j.molonc.2015.03.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
430 Velic D, Couturier AM, Ferreira MT, Rodrigue A, Poirier GG, Fleury F, Masson JY. DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer. Biomolecules 2015;5:3204-59. [PMID: 26610585 DOI: 10.3390/biom5043204] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 10.0] [Reference Citation Analysis]
431 Mini E, Landini I, Lucarini L, Lapucci A, Napoli C, Perrone G, Tassi R, Masini E, Moroni F, Nobili S. The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. Oncol Res 2017;25:1441-51. [PMID: 28429680 DOI: 10.3727/096504017X14926854178616] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
432 Curtin NJ. Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer. Br J Pharmacol 2013;169:1745-65. [PMID: 23682925 DOI: 10.1111/bph.12244] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
433 Labrie M, Kim TB, Ju Z, Lee S, Zhao W, Fang Y, Lu Y, Chen K, Ramirez P, Frumovitz M, Meyer L, Fleming ND, Sood AK, Coleman RL, Mills GB, Westin SN. Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget 2019;10:3533-46. [PMID: 31191824 DOI: 10.18632/oncotarget.26947] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
434 Lobo J, Constâncio V, Guimarães-Teixeira C, Leite-Silva P, Miranda-Gonçalves V, Sequeira JP, Pistoni L, Guimarães R, Cantante M, Braga I, Maurício J, Looijenga LHJ, Henrique R, Jerónimo C. Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors. Mol Oncol 2021;15:846-65. [PMID: 33513287 DOI: 10.1002/1878-0261.12909] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
435 Konstantinopoulos PA, Matulonis UA. Current status and evolution of preclinical drug development models of epithelial ovarian cancer. Front Oncol 2013;3:296. [PMID: 24377084 DOI: 10.3389/fonc.2013.00296] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
436 Oliveira DVNP, Prahm KP, Christensen IJ, Hansen A, Høgdall CK, Høgdall EV. Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases. Reprod Sci 2021;28:757-65. [PMID: 33125686 DOI: 10.1007/s43032-020-00372-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
437 Koczkowska M, Krawczynska N, Stukan M, Kuzniacka A, Brozek I, Sniadecki M, Debniak J, Wydra D, Biernat W, Kozlowski P, Limon J, Wasag B, Ratajska M. Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients. Cancers (Basel) 2018;10:E442. [PMID: 30441849 DOI: 10.3390/cancers10110442] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
438 van de Ven AL, Tangutoori S, Baldwin P, Qiao J, Gharagouzloo C, Seitzer N, Clohessy JG, Makrigiorgos GM, Cormack R, Pandolfi PP, Sridhar S. Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation. Mol Cancer Ther 2017;16:1279-89. [PMID: 28500233 DOI: 10.1158/1535-7163.MCT-16-0740] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
439 Buisson R, Dion-Côté AM, Coulombe Y, Launay H, Cai H, Stasiak AZ, Stasiak A, Xia B, Masson JY. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol 2010;17:1247-54. [PMID: 20871615 DOI: 10.1038/nsmb.1915] [Cited by in Crossref: 205] [Cited by in F6Publishing: 183] [Article Influence: 18.6] [Reference Citation Analysis]
440 Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 2011;10:1192-1199. [PMID: 21487248 DOI: 10.4161/cc.10.8.15273] [Cited by in Crossref: 107] [Cited by in F6Publishing: 100] [Article Influence: 10.7] [Reference Citation Analysis]
441 Capoluongo E. BRCA to the future: towards best testing practice in the era of personalised healthcare. Eur J Hum Genet 2016;24 Suppl 1:S1-2. [PMID: 27514838 DOI: 10.1038/ejhg.2016.92] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
442 Suszynska M, Ratajska M, Kozlowski P. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. J Ovarian Res 2020;13:50. [PMID: 32359370 DOI: 10.1186/s13048-020-00654-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
443 Gonzalo S. Novel roles of 1α,25(OH)2D3 on DNA repair provide new strategies for breast cancer treatment. J Steroid Biochem Mol Biol 2014;144 Pt A:59-64. [PMID: 24080249 DOI: 10.1016/j.jsbmb.2013.09.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
444 Sistigu A, Manic G, Obrist F, Vitale I. Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol 2016;3:e1053594. [PMID: 27308587 DOI: 10.1080/23723556.2015.1053594] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
445 Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 2015;13:188. [PMID: 26268938 DOI: 10.1186/s12916-015-0425-1] [Cited by in Crossref: 160] [Cited by in F6Publishing: 148] [Article Influence: 26.7] [Reference Citation Analysis]
446 Caster JM, Sethi M, Kowalczyk S, Wang E, Tian X, Nabeel Hyder S, Wagner KT, Zhang YA, Kapadia C, Man Au K, Wang AZ. Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity. Nanoscale 2015;7:2805-11. [PMID: 25584654 DOI: 10.1039/c4nr07102f] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
447 Baldock RA, Pressimone CA, Baird JM, Khodakov A, Luong TT, Grundy MK, Smith CM, Karpenshif Y, Bratton-Palmer DS, Prakash R, Jasin M, Garcin EB, Gon S, Modesti M, Bernstein KA. RAD51D splice variants and cancer-associated mutations reveal XRCC2 interaction to be critical for homologous recombination. DNA Repair (Amst) 2019;76:99-107. [PMID: 30836272 DOI: 10.1016/j.dnarep.2019.02.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
448 Hosoya N, Miyagawa K. Targeting DNA damage response in cancer therapy. Cancer Sci. 2014;105:370-388. [PMID: 24484288 DOI: 10.1111/cas.12366] [Cited by in Crossref: 167] [Cited by in F6Publishing: 161] [Article Influence: 23.9] [Reference Citation Analysis]
449 Yoshino Y, Endo S, Chen Z, Qi H, Watanabe G, Chiba N. Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency. Sci Rep 2019;9:1644. [PMID: 30733539 DOI: 10.1038/s41598-018-38311-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
450 Pölsler L, Fiegl H, Wimmer K, Oberaigner W, Amberger A, Traunfellner P, Morscher RJ, Weber I, Fauth C, Wernstedt A, Sperner-Unterweger B, Oberguggenberger A, Hubalek M, Marth C, Zschocke J. High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing. Eur J Hum Genet 2016;24:258-62. [PMID: 26014432 DOI: 10.1038/ejhg.2015.108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
451 Alenezi WM, Fierheller CT, Recio N, Tonin PN. Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers. Genes (Basel) 2020;11:E856. [PMID: 32726901 DOI: 10.3390/genes11080856] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
452 Iyevleva AG, Imyanitov EN. Cytotoxic and targeted therapy for hereditary cancers. Hered Cancer Clin Pract. 2016;14:17. [PMID: 27555886 DOI: 10.1186/s13053-016-0057-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
453 Hussain M, Carducci MA, Slovin S, Cetnar J, Qian J, McKeegan EM, Refici-Buhr M, Chyla B, Shepherd SP, Giranda VL, Alumkal JJ. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 2014;32:904-12. [PMID: 24764124 DOI: 10.1007/s10637-014-0099-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 7.6] [Reference Citation Analysis]
454 Zhang JF, Liu J, Wang Y, Zhang B. Novel therapeutic strategies for patients with triple-negative breast cancer. Onco Targets Ther. 2016;9:6519-6528. [PMID: 27799799 DOI: 10.2147/ott.s105716] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
455 Pirinen E, Cantó C, Jo YS, Morato L, Zhang H, Menzies KJ, Williams EG, Mouchiroud L, Moullan N, Hagberg C, Li W, Timmers S, Imhof R, Verbeek J, Pujol A, van Loon B, Viscomi C, Zeviani M, Schrauwen P, Sauve AA, Schoonjans K, Auwerx J. Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab 2014;19:1034-41. [PMID: 24814482 DOI: 10.1016/j.cmet.2014.04.002] [Cited by in Crossref: 156] [Cited by in F6Publishing: 156] [Article Influence: 22.3] [Reference Citation Analysis]
456 Suh DH, Kim K, Kim JW. Major clinical research advances in gynecologic cancer in 2011. J Gynecol Oncol 2012;23:53-64. [PMID: 22355468 DOI: 10.3802/jgo.2012.23.1.53] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
457 Alhmoud JF, Woolley JF, Al Moustafa AE, Malki MI. DNA Damage/Repair Management in Cancers. Cancers (Basel). 2020;12:1050. [PMID: 32340362 DOI: 10.3390/cancers12041050] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 23.0] [Reference Citation Analysis]
458 Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov. 2015;5:1137-1154. [PMID: 26463832 DOI: 10.1158/2159-8290.cd-15-0714] [Cited by in Crossref: 347] [Cited by in F6Publishing: 205] [Article Influence: 57.8] [Reference Citation Analysis]
459 Arora E, Masab M, Jindal V, Riaz I, Gupta S, Varadi G. Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer. Cureus 2018;10:e2685. [PMID: 30050740 DOI: 10.7759/cureus.2685] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
460 Lattanzi M, Balar AV. Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma. Curr Oncol Rep 2019;21:24. [PMID: 30806823 DOI: 10.1007/s11912-019-0775-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
461 O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, Stadler ZK, Do RKG, Dhani N, Chen AP, Kelsen DP. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol 2020;38:1378-88. [PMID: 31976786 DOI: 10.1200/JCO.19.02931] [Cited by in Crossref: 83] [Cited by in F6Publishing: 44] [Article Influence: 83.0] [Reference Citation Analysis]
462 Guidugli L, Carreira A, Caputo SM, Ehlen A, Galli A, Monteiro AN, Neuhausen SL, Hansen TV, Couch FJ, Vreeswijk MP; ENIGMA consortium. Functional assays for analysis of variants of uncertain significance in BRCA2. Hum Mutat 2014;35:151-64. [PMID: 24323938 DOI: 10.1002/humu.22478] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 9.1] [Reference Citation Analysis]
463 Zhang G, Liu C, Bai H, Cao G, Cui R, Zhang Z. Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment. Oncol Lett 2019;17:2583-91. [PMID: 30854033 DOI: 10.3892/ol.2019.9902] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
464 Terashima M, Sakai K, Togashi Y, Hayashi H, De Velasco MA, Tsurutani J, Nishio K. Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines. Springerplus 2014;3:417. [PMID: 25140293 DOI: 10.1186/2193-1801-3-417] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
465 de Haan R, van Werkhoven E, van den Heuvel MM, Peulen HMU, Sonke GS, Elkhuizen P, van den Brekel MWM, Tesselaar MET, Vens C, Schellens JHM, van Triest B, Verheij M. Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. BMC Cancer 2019;19:901. [PMID: 31500595 DOI: 10.1186/s12885-019-6121-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
466 Runkle EA, Zhang H, Cai Z, Zhu Z, Karger BL, Wu SL, O'Rourke DM, Zhou Z, Wang Q, Greene MI. Reversion of the ErbB malignant phenotype and the DNA damage response. Exp Mol Pathol 2012;93:324-33. [PMID: 23022358 DOI: 10.1016/j.yexmp.2012.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
467 Wilkerson PM, Dedes KJ, Samartzis EP, Dedes I, Lambros MB, Natrajan R, Gauthier A, Piscuoglio S, Töpfer C, Vukovic V, Daley F, Weigelt B, Reis-Filho JS. Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer. Oncotarget 2017;8:6057-66. [PMID: 28002809 DOI: 10.18632/oncotarget.14011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
468 Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS. Appraising iniparib, the PARP inhibitor that never was--what must we learn? Nat Rev Clin Oncol 2013;10:688-96. [PMID: 24129347 DOI: 10.1038/nrclinonc.2013.177] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.9] [Reference Citation Analysis]
469 Lim JSJ, Tan DSP. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers (Basel) 2017;9:E109. [PMID: 28829366 DOI: 10.3390/cancers9080109] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
470 Sajesh BV, Guppy BJ, McManus KJ. Synthetic genetic targeting of genome instability in cancer. Cancers (Basel) 2013;5:739-61. [PMID: 24202319 DOI: 10.3390/cancers5030739] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
471 Tung NM, Garber JE. BRCA1/2 testing: therapeutic implications for breast cancer management. Br J Cancer 2018;119:141-52. [PMID: 29867226 DOI: 10.1038/s41416-018-0127-5] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 23.0] [Reference Citation Analysis]
472 Abbotts R, Thompson N, Madhusudan S. DNA repair in cancer: emerging targets for personalized therapy. Cancer Manag Res 2014;6:77-92. [PMID: 24600246 DOI: 10.2147/CMAR.S50497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
473 Imyanitov EN, Moiseyenko VM. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011;9:5. [PMID: 21819606 DOI: 10.1186/1897-4287-9-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
474 Sehouli J, Braicu EI, Chekerov R. PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives. Geburtshilfe Frauenheilkd 2016;76:164-9. [PMID: 26941449 DOI: 10.1055/s-0035-1558185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
475 Villalona-Calero MA, Duan W, Zhao W, Shilo K, Schaaf LJ, Thurmond J, Westman JA, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 2016;108. [PMID: 26848151 DOI: 10.1093/jnci/djv437] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
476 Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev 2020;34:360-94. [PMID: 32029455 DOI: 10.1101/gad.334516.119] [Cited by in Crossref: 83] [Cited by in F6Publishing: 83] [Article Influence: 83.0] [Reference Citation Analysis]
477 Marques M, Beauchamp MC, Fleury H, Laskov I, Qiang S, Pelmus M, Provencher D, Mes-Masson AM, Gotlieb WH, Witcher M. Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors. BMC Med 2015;13:217. [PMID: 26354718 DOI: 10.1186/s12916-015-0454-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
478 Krukenberg KA, Jiang R, Steen JA, Mitchison TJ. Basal activity of a PARP1-NuA4 complex varies dramatically across cancer cell lines. Cell Rep 2014;8:1808-18. [PMID: 25199834 DOI: 10.1016/j.celrep.2014.08.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
479 Crespan E, Garbelli A, Amoroso A, Maga G. Exploiting the nucleotide substrate specificity of repair DNA polymerases to develop novel anticancer agents. Molecules 2011;16:7994-8019. [PMID: 21926946 DOI: 10.3390/molecules16097994] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
480 Koppensteiner R, Samartzis EP, Noske A, von Teichman A, Dedes I, Gwerder M, Imesch P, Ikenberg K, Moch H, Fink D, Stucki M, Dedes KJ. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro. PLoS One 2014;9:e100041. [PMID: 24927325 DOI: 10.1371/journal.pone.0100041] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
481 Glaser G, Weroha SJ, Becker MA, Hou X, Enderica-Gonzalez S, Harrington SC, Haluska P. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. PLoS One 2015;10:e0126867. [PMID: 25962155 DOI: 10.1371/journal.pone.0126867] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
482 Brown JS, O'Carrigan B, Jackson SP, Yap TA. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov 2017;7:20-37. [PMID: 28003236 DOI: 10.1158/2159-8290.CD-16-0860] [Cited by in Crossref: 255] [Cited by in F6Publishing: 149] [Article Influence: 51.0] [Reference Citation Analysis]
483 Neff RT, Senter L, Salani R. BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol 2017;9:519-31. [PMID: 28794804 DOI: 10.1177/1758834017714993] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
484 Sie AS, Spruijt L, van Zelst-Stams WA, Mensenkamp AR, Ligtenberg MJ, Brunner HG, Prins JB, Hoogerbrugge N. DNA-testing for BRCA1/2 prior to genetic counselling in patients with breast cancer: design of an intervention study, DNA-direct. BMC Womens Health 2012;12:12. [PMID: 22569005 DOI: 10.1186/1472-6874-12-12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
485 Yu L, Liu X, Yu X. ADP-ribosylhydrolases: from DNA damage repair to COVID-19. J Zhejiang Univ Sci B 2021;22:21-30. [PMID: 33448184 DOI: 10.1631/jzus.B2000319] [Reference Citation Analysis]
486 Bixel K, Hays JL. Olaparib in the management of ovarian cancer. Pharmgenomics Pers Med 2015;8:127-35. [PMID: 26309417 DOI: 10.2147/PGPM.S62809] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
487 Lin ZP, Zhu YL, Lo YC, Moscarelli J, Xiong A, Korayem Y, Huang PH, Giri S, LoRusso P, Ratner ES. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. PLoS One 2018;13:e0207399. [PMID: 30444904 DOI: 10.1371/journal.pone.0207399] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
488 Wang D, Du R, Liu S. Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer. Chin J Cancer 2017;36:37. [PMID: 28359295 DOI: 10.1186/s40880-017-0204-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
489 Huang YW. Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis. Medicine (Baltimore) 2018;97:e9380. [PMID: 29480828 DOI: 10.1097/MD.0000000000009380] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
490 Nowsheen S, Cooper T, Bonner JA, LoBuglio AF, Yang ES. HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res 2012;72:4796-806. [PMID: 22987487 DOI: 10.1158/0008-5472.CAN-12-1287] [Cited by in Crossref: 40] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
491 Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE. A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. Clin Cancer Res 2017;23:697-706. [PMID: 27503200 DOI: 10.1158/1078-0432.CCR-16-0984] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
492 Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. Br J Cancer 2017;116:884-92. [PMID: 28222073 DOI: 10.1038/bjc.2017.36] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
493 Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH. Advances in using PARP inhibitors to treat cancer. BMC Med 2012;10:25. [PMID: 22401667 DOI: 10.1186/1741-7015-10-25] [Cited by in Crossref: 95] [Cited by in F6Publishing: 88] [Article Influence: 10.6] [Reference Citation Analysis]
494 Dean M, Boland J, Yeager M, Im KM, Garland L, Rodriguez-Herrera M, Perez M, Mitchell J, Roberson D, Jones K, Lee HJ, Eggebeen R, Sawitzke J, Bass S, Zhang X, Robles V, Hollis C, Barajas C, Rath E, Arentz C, Figueroa JA, Nguyen DD, Nahleh Z. Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2. Gigascience 2015;4:50. [PMID: 26543556 DOI: 10.1186/s13742-015-0088-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
495 Rehman FL, Lord CJ, Ashworth A. Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 2010;7:718-24. [PMID: 20956981 DOI: 10.1038/nrclinonc.2010.172] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 5.8] [Reference Citation Analysis]
496 Obermair A, Beale P, Scott CL, Beshay V, Kichenadasse G, Simcock B, Nicklin J, Lee YC, Cohen P, Meniawy T. Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. J Gynecol Oncol 2021;32:e95. [PMID: 34708597 DOI: 10.3802/jgo.2021.32.e95] [Reference Citation Analysis]
497 Mariano G, Ricciardi MR, Trisciuoglio D, Zampieri M, Ciccarone F, Guastafierro T, Calabrese R, Valentini E, Tafuri A, Del Bufalo D, Caiafa P, Reale A. PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression. Oncotarget 2015;6:15008-21. [PMID: 25938539 DOI: 10.18632/oncotarget.3634] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
498 Park SH, Jang KY, Kim MJ, Yoon S, Jo Y, Kwon SM, Kim KM, Kwon KS, Kim CY, Woo HG. Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications. Oncotarget 2015;6:44819-31. [PMID: 26540566 DOI: 10.18632/oncotarget.6264] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
499 Wu Z, Li S, Tang X, Wang Y, Guo W, Cao G, Chen K, Zhang M, Guan M, Yang D. Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer. Theranostics 2020;10:3939-51. [PMID: 32226530 DOI: 10.7150/thno.39341] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
500 Incorvaia L, Passiglia F, Rizzo S, Galvano A, Listì A, Barraco N, Maragliano R, Calò V, Natoli C, Ciaccio M, Bazan V, Russo A. "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors. Oncotarget 2017;8:23891-904. [PMID: 28055979 DOI: 10.18632/oncotarget.14409] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
501 Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH, Yasmeen A. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer 2017;17:638. [PMID: 28886696 DOI: 10.1186/s12885-017-3639-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
502 Quesada A, O'Valle F, Montoro-Molina S, Gómez-Morales M, Caba-Molina M, González JF, de Gracia MC, Osuna A, Vargas F, Wangensteen R. 5-aminoisoquinoline improves renal function and fibrosis during recovery phase of cisplatin-induced acute kidney injury in rats. Biosci Rep 2018;38:BSR20171313. [PMID: 29599129 DOI: 10.1042/BSR20171313] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
503 Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW, Callif-Daley F, Grumet SC, Hunt KS, Nagy RS, McKinnon WC, Petrucelli NM, Bennett RL, Trepanier AM. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 2012;21:151-61. [PMID: 22134580 DOI: 10.1007/s10897-011-9462-x] [Cited by in Crossref: 211] [Cited by in F6Publishing: 168] [Article Influence: 21.1] [Reference Citation Analysis]
504 Meisel JL, Hyman DM, Garg K, Zhou Q, Dao F, Bisogna M, Gao J, Schultz ND, Grisham RN, Phillips M, Iasonos A, Kauff ND, Levine DA, Soslow RA, Spriggs DR. The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. Ann Oncol 2014;25:2372-8. [PMID: 25281711 DOI: 10.1093/annonc/mdu461] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
505 Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer. Gynecol Oncol 2014;134:331-7. [PMID: 24844596 DOI: 10.1016/j.ygyno.2014.05.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
506 Larsen MJ, Thomassen M, Gerdes AM, Kruse TA. Hereditary breast cancer: clinical, pathological and molecular characteristics. Breast Cancer (Auckl) 2014;8:145-55. [PMID: 25368521 DOI: 10.4137/BCBCR.S18715] [Cited by in Crossref: 11] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
507 Jekimovs C, Bolderson E, Suraweera A, Adams M, O'Byrne KJ, Richard DJ. Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising. Front Oncol 2014;4:86. [PMID: 24795863 DOI: 10.3389/fonc.2014.00086] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 9.9] [Reference Citation Analysis]
508 Ma S, Pradeep S, Villar-Prados A, Wen Y, Bayraktar E, Mangala LS, Kim MS, Wu SY, Hu W, Rodriguez-Aguayo C, Leuschner C, Liang X, Ram PT, Schlacher K, Coleman RL, Sood AK. GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition. Mol Cancer Ther 2019;18:969-79. [PMID: 30926640 DOI: 10.1158/1535-7163.MCT-18-0770] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
509 Shaw HM, Hall M. Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. Onco Targets Ther 2013;6:1197-206. [PMID: 24043945 DOI: 10.2147/OTT.S30748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
510 Williamson SR, Cheng L. Potential for targeted therapy in prostate cancers with ERG abnormalities. Asian J Androl 2011;13:781-2. [PMID: 21785441 DOI: 10.1038/aja.2011.100] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
511 Osoegawa A, Gills JJ, Kawabata S, Dennis PA. Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib. Oncotarget 2017;8:87044-53. [PMID: 29152062 DOI: 10.18632/oncotarget.19667] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
512 Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, Wang X, Gao Y, Yu F, Su D, Wang F, Zhu Y, Zhao Y, Wu Y, Qin Z, Sun X, Ren B, Jiang B, Jin W, Shen Z, Tang Z, Song X, Wang L, Liu X, Zhou C, Jiang B. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia 2020;22:431-40. [PMID: 32652442 DOI: 10.1016/j.neo.2020.06.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
513 Leichman L, Groshen S, O’Neil BH, Messersmith W, Berlin J, Chan E, Leichman CG, Cohen SJ, Cohen D, Lenz HJ. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. Oncologist. 2016;21:172-177. [PMID: 26786262 DOI: 10.1634/theoncologist.2015-0319] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
514 Chen YX, Tan LM, Gong JP, Huang MS, Yin JY, Zhang W, Zhou HH, Liu ZQ. Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer. Acta Pharmacol Sin 2021. [PMID: 33589795 DOI: 10.1038/s41401-020-00604-1] [Reference Citation Analysis]
515 Liu J, Westin SN. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. Gynecol Oncol 2016;141:65-71. [PMID: 27016231 DOI: 10.1016/j.ygyno.2016.01.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
516 Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P, Pazdur R. Successes and Challenges of PARP Inhibitors in Cancer Therapy. Front Oncol 2015;5:222. [PMID: 26528434 DOI: 10.3389/fonc.2015.00222] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]